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ABSTRACT 
In light of the increasing, but insufficient, evidence that various infections and 
immunological processes during brain development are associated with psychotic disorder, 
the aim of this thesis was to investigate infection during foetal life and childhood on the 
risk of developing non-affective psychosis later in life. We conducted two population-based 
birth cohort studies using linkages to several nationwide registers as well as two studies on 
a subset of cases and controls in which biological samples were examined.  
          In Study I, the association between specific chronic maternal infections during 
pregnancy and non-affective psychoses in the offspring was assessed. For that purpose we 
analysed levels of antibodies in neonatal dried blood samples (NDBS) directed at four 
neurotropic agents; Toxoplasma gondii (T. gondii), cytomegalovirus (CMV) as well as 
herpes simplex virus type 1 and 2. Maternal T. gondii and CMV infections were found to be 
associated with schizophrenia.  
          In Study II, chronic maternal infection during pregnancy, neonatal immune markers, 
and subsequent non-affective psychosis were investigated. NDBS were analysed to 
determine levels of antibodies directed at T. gondii and three herpes viruses as well as 
levels of acute phase proteins (APPs; immune markers). Maternal infection with T. gondii 
and CMV was associated with a change in APPs among controls but not among individuals 
who later develop non-affective psychosis. Furthermore, interaction between maternal 
infection and low levels of APP in the development of psychotic disorder was indicated. 
          In Study III, the association between hospital admission for infection during 
childhood (0-13 years of age) and the risk of developing non-affective psychosis was 
examined. Additionally, possible vulnerable ages, and type of infection (virus and bacteria 
as well as infection of the central nervous system (CNS)) were scrutinized. Any infection 
during childhood was modestly associated with non-affective psychosis later in life. The 
strongest estimates were found for bacterial infection and infection of the CNS during pre-
adolescence (10-13 years of age).  
          In Study IV, the association between maternal infection during pregnancy and non-
affective psychosis was investigated. We found no evidence of such association. However, 
maternal infection during pregnancy and maternal psychiatric disorder interacted in the 
development of psychosis among offspring. Additionally, associations between maternal 
infection during pregnancy and offspring childhood infection were investigated. Maternal 
infection increased the relative risk of offspring childhood infection, two factors that 
interacted in the development of non-affective psychosis.   
          In conclusion, there were no strong associations between infection during foetal life 
or childhood and non-affective psychosis overall. However, neonates with mothers exposed 
to T. gondii and CMV infection had substantial increased relative risks of developing 
psychosis, especially in conjunction with an altered immune response. The interactions 
between infection during foetal life and genetic vulnerability, neonatal immune alterations 
as well as with childhood infections in the development of non-affective psychosis indicate 
that maternal infection during pregnancy does play an important role in the aetiology.  
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1 INTRODUCTION 
Non-affective psychoses including schizophrenia are in many cases disabling mental 
disorders associated with symptoms such as hallucination, delusion and cognitive deficit, 
which are usually detected and become clinically relevant in early adulthood. In Sweden, 
psychotic disorders account for approximately 35% of all psychiatric inpatient care 
1
. The 
total cost, including medical care, production loss, and social welfare benefits, is estimated at 
25 billion SEK per year 
2
. Such disorders constitute a heavy burden for both the affected 
individual and her/his family members, due to lifelong medical treatment, stigmatization, and 
alienation from society . 
 
The aetiology of non-affective psychotic disorders is unknown, but increasing evidence 
suggest that schizophrenia is a neurodevelopmental disorder 
3
. Family studies indicate the 
presence of a strong genetic factor, but no specific gene(s) have yet been identified 
4,5
. In fact, 
most individuals who develope psychotic disorder do not have relatives with psychosis 
6
. It is 
likely that a combination of genetic vulnerability and one or more environmental factor/-s 
causes the development of the disorder 
7,8
, suggestive of a two-hit model. Numerous 
environmental risk factors present during brain development have been proposed, e.g., 
perinatal complications 
9,10
, winter season birth 
11
, urban upbringing 
12
, and infection 
13,14
. 
 
The observed excess of winter births among individuals who later develop psychosis and the 
growing interest in the theory of disturbed neurodevelopment in the aetiology of psychosis 
has led to the hypothesis of infection during brain development as a risk factor for psychotic 
disorder 
15
. It is well known that certain congenital infections (e.g., rubella virus) can disturb  
neurodevelopmental processes and cause persistent sequelae ranging from mild to severe 
16
. 
Despite the fact that studies with an ecological design, small studies based on individual data 
or biological samples as well as animal experimental studies collectively indicate an 
association between exposure to an infection early in life and adult psychosis, the results are 
inconclusive and further research is nessesary 
13,14,17,18
. Moreover, brain development is not 
confined to the foetal period but continues throughout childhood and early adulthood 
19
. 
Nevertheless, studies investigating the association between infection during these years on 
the subsequent development of psychotic disorder are sparse and their results ambiguous 
14
. 
 
The overall aim of the present thesis is to scrutinize the role of infection during foetal life and 
childhood in relation to the risk of developing non-affective psychosis, by combining 
population based registers and individual biological samples. The thesis will hopefully 
contribute to the understanding of the risk of exposure to infection early in life in relation to 
psychotic disorder. 
Figure 1 illustrates infection during foetal life and childhood in relation to the development of 
psychotic disorder. 
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2 BACKGROUND 
2.1 NON-AFFECTIVE PSYCHOSIS INCLUDING SCHIZOPHRENIA 
2.1.1 Symptoms and diagnostic criteria  
Schizophrenia is the most common syndrome among the large group of non-affective 
psychoses, accounting for about 50% of cases 
20
. For a diagnosis of schizophrenia there must 
be both psychotic symptoms of a disturbed perception of reality and a social or occupational 
loss of functioning for a certain period of time. The diagnosis is thus based on symptoms, 
function and progression. Individuals diagnosed with schizophrenia exhibit positive 
symptoms such as: hallucinations, delusions, thought disorder, and disorganized or catatonic 
behaviour, as well as negative symptoms such as: apathy, monotonic speech, and flat facial 
expressions and with more or less cognitive deficit 
21
. Other syndromes within the large 
group of non-affective psychoses have similar symptoms but some may be more accentuated, 
or of shorter duration.  
There are two diagnostic manuals used by psychiatric clinicians and researchers in many 
parts of the world: the Diagnostic and Statistical Manual of Mental Disorders (DSM) 
developed by the American Psychiatric Association and the WHO International Classification 
of Diseases (ICD). The specific criteria in ICD-10 for a diagnosis of schizophrenia can be 
found below. The various editions of the two manuals have been gradually coordinated, but 
there is one significant difference between the two systems: according to the DSM-IV, the 
requirement for a diagnosis is one month of specific symptoms and at least six months of 
functional loss, while in the ICD-10 the symptoms must be present for at least one month 
before the diagnosis can be made, thus the criteria is somewhat broader than in the DSM-IV. 
In Sweden, the health care registration system only allows ICD codes.  
The disorder typically develops gradually during a prodromal phase in late adolescence with 
a psychotic episode resulting in admission and a diagnosis a few years later 
22
. Usually men 
develop the disorder earlier than women with a mean age of 28.2 years at first admission, 
whereas women have a mean age of 32.2 years at first admission 
23
. In addition, men appear 
to have a more serious disease course including more cognitive dysfunctions, alcohol and 
substance abuse 
24
. 
In this thesis the terms non-affective psychosis, psychotic disorder and psychosis will be used 
interchangeably. However, the terms always refer to non-affective psychosis. Thus, affective 
psychoses are not included. 
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ICD-10 diagnostic criteria for schizophrenia  
 
F20 SCHIZOPHRENIA (ICD-10 criteria 
25
) 
 
G1. Either at least one of the syndromes, symptoms and signs listed below under (1), or at least two of the 
symptoms and signs listed under (2), should be present for most of the time during an episode of psychotic illness 
lasting for at least one month (or at some time during most of the days). 
 
1. At least one of the following: 
a. Thought echo, thought insertion or withdrawal, or thought broadcasting. 
b.  Delusions of control, influence or passivity, clearly referred to body or limb movements or specific 
thoughts, actions, or sensations; delusional perception. 
c.  Hallucinatory voices giving a running commentary on the patient's behaviour, or discussing him 
between themselves, or other types of hallucinatory voices coming from some part of the body. 
d.  Persistent delusions of other kinds that are culturally inappropriate and completely impossible (e.g. 
being able to control the weather, or being in communication with aliens from another world). 
2. or at least two of the following: 
e.  Persistent hallucinations in any modality, when occurring every day for at least one month, when 
accompanied by delusions (which may be fleeting or half-formed) without clear affective content, or 
when accompanied by persistent over-valued ideas. 
f. Neologisms, breaks or interpolations in the train of thought, resulting in incoherence or irrelevant 
speech. 
g. Catatonic behaviour, such as excitement, posturing or waxy flexibility, negativism, mutism and 
stupor. 
h. "Negative" symptoms such as marked apathy, paucity of speech, and blunting or incongruity of 
emotional responses (it must be clear that these are not due to depression or to neuroleptic 
medication). 
 
G2. Most commonly used exclusion criteria: If the patient also meets criteria for manic episode (F30) or depressive 
episode (F32), the criteria listed under G1.1 and G1.2 above must have been met before the disturbance of mood 
developed. 
 
G3. The disorder is not attributable to organic brain disease (in the sense of F0), or to alcohol- or drug-related 
intoxication, dependence or withdrawal. 
 
2.1.2 Incidence and prevalence 
The incidence of schizophrenia varies across geographic areas, both between and within 
countries. To date, the largest systematic review of the incidence of schizophrenia includes 55 
studies from 33 countries and report a median incidence rate of 15.2 (7.7-43) per 100 000 
persons, and with a males-females ratio of 1.4:1 
26
. In general, higher incidence rates are 
observed in urban areas and among migrants. 
While incidence rate refers to the number of new cases of a disease per population at risk per 
time unit, prevalence is the number of cases in a population at a given time point. In a large 
systematic review including 142 studies from 46 countries, Saha et al., reported the 
prevalence to be 4.6 (1.9-10.0) per 1 000 individuals 
27
. Less developed countries tended to 
have lower prevalences than more developed countries.  
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There are no reports on incidence or prevalence for the whole of Sweden. However, 
Jörgensen et al., recently reported on the incidence and prevalence of schizophrenia and non-
affective psychosis, respectively in Stockholm County Council 
20,28
. The incidence of 
schizophrenia was 28 per 100 000 individuals, while in the more broadly defined group of 
non-affective psychoses, the incidence was 78 per 100 000. The one year prevalence was 
estimated at 3.7 per 1 000 individuals for schizophrenia, and 6.7 per 1 000 individuals for the 
larger group of non-affective psychoses. 
2.1.3 Neurodevelopmental hypothesis 
When Kraepelin first described schizophrenia over a hundred years ago, he used the term 
Dementia praecox, indicating a degenerative process 
29
. Schizophrenia was long considered a 
neurodegenerative disorder like Alzheimer´s disease. However, in 1987 the 
neurodevelopmental hypothesis was presented 
30,31
. Although the hypothesis of a progressive 
degenerative course has not been disregarded 
32,33
, evidence of disturbed neurodevelopment 
in schizophrenia has been amassing 
34
: brain morphological changes present before onset and 
not correlating with disease duration are reported 
35-37
.  In contrast, gliosis, which is normally 
seen in degenerative brain disorders, is not present 
38,39
. Moreover, prenatal and early 
childhood complications such as obstetric complications, delayed motor development, and 
lower cognitive abilities are more common among individuals who develop schizophrenia 
10,40-43
. In addition, genetic studies (GWAS) have reported variations in genes involved in 
brain development 
5
. More recently, it has been suggested that the two theories of 
neurodevelopmental insults and degeneration are not to be mutually exclusive but linked with 
each other 
44,45
. 
2.1.4 Genetic risk and environmental influences 
At an individual level, the strongest risk factor for developing schizophrenia is having a first 
degree relative with the disorder 
46
. However, most individuals who develop schizophrenia do 
not have any family history of the disorder. No causal gene has so far been identified. 
However, GWAS have found common genomic variations such as single nucleotide 
polymorphisms (SNPs) 
5
 as well as rare variations, e.g., copy number variations (CNVs) 
4
, to 
be associated with schizophrenia. A SNP is a DNA-site anywhere on the genome where one 
single nucleotide base pair varies between individuals. Currently over 100 common SNPs 
have been associated with schizophrenia and appear to cluster in genes involved in CNS 
functions 
47
. Some of the strongest associations have been observed in the major 
histocompatibility complex (MHC) region on chromosome 6. This region is dense with genes 
associated with the immune system but also genes that are involved in brain development and 
plasticity 
48,49
. CNVs are rare structural variations that include a large number of base pairs 
ranging from thousands to millions that have been either deleted, or duplicated. These can be 
situated inside or outside genes and may be inherited or appear de novo. Patients with 
schizophrenia appear to harbour more CNVs than controls, some of which are situated within 
genes important for brain development and immunity 
4,50,51
.  
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Among affected monozygotic twins, both twins have the disorder in 40-60% of cases 
52
, 
which indicates a substantial contribution of environmental effects. It is likely that genetic 
factors and one or more environmental factors are needed to develop the disease. Interactions 
between genetic and environmental factors such as infection have in fact been suggested in 
schizophrenia aetiology 
8
. 
2.2 INFECTIONS EARLY IN LIFE – POTENTIAL RISK FACTORS FOR NON-
AFFECTIVE PSYCHOSIS 
The theory of neurodevelopmental insults in schizophrenia aetiology, the increasing 
knowledge of various pathogens causing congenital brain anomalies, the awareness of 
psychotic symptoms during certain infections and birth excess during the winter months 
(when viral infections are highly prevalent) among children who later develope schizophrenia 
increased the interest in prenatal exposure to viral infection in the aetiology of schizophrenia 
in the 1970s 
53
. In 1988, Mednick et al., presented their seminal study of the increased 
incidence of schizophrenia among children born in Finland during the influenza epidemic in 
1957 
15
. Since then, maternal Influenza A infection during pregnancy has been the topic of 
numerous studies. Most of these studies have used an ecological design without information 
about exposure at an individual level and the results have been contradictory 
54
. 
After the idea of prenatal infection in the aetiology of psychotic disorder was presented, 
several studies on this association were conducted using individual data. Some investigated 
biological samples (sera and blood), while others examined clinical diagnoses. A summary of 
these studies is presented below.  
It is important to note that in the context of investigating maternal infection during pregnancy 
in schizophrenia research terms, such as “prenatal infection”, “foetal exposure to infection”, 
or “infection during foetal life” are often used. However, these terms actually refer to 
maternal infection during pregnancy. Whether the foetus is infected is not known. In this 
thesis these terms will be used interchangeably, but always refer to maternal infection during 
pregnancy.  
2.2.1.1 Studies using biological samples 
Basically, there are three ways of detecting infection in sera or blood: by direct detection 
which can be done by culture (a certain amount of blood is needed), by detecting microbial 
genomes using the PCR-technique or by testing for the presence of antibodies specifically 
directed at a certain microbe (serology). This latter approach has the advantage of being 
sensitive, cheap and capable of detecting exposures long after the microbe is cleared by the 
host immune system.  
Serology determines antigen-specific immunity in terms of levels of antibodies directed at the 
specific pathogen. Antibodies are part of the adaptive immune response, which is a specific 
defense against a certain pathogen. Immunoglobulin M (IgM) antibodies are the first 
antibodies to be produced within 1-2 weeks after exposure. They are only detectable for a few 
  13 
weeks and gradually replaced by immunoglobulin G (IgG) antibodies. IgM detection 
therefore indicates an ongoing or recent infection. IgG antibodies are produced after a couple 
of weeks and can usually be detected for years after exposure. Thus, IgG detection reveals 
whether or not an individual has been exposed but does not provide information about when 
the exposure occurred. Neonatal blood harbours levels of IgG mainly derived from the 
mother and transferred across the placenta during pregnancy to provide the newborn with 
passive immunization 
55
. Thus, IgG in maternal sera and in neonatal blood mirrors maternal 
exposure to an infection at some time prior to testing/delivery.   
A few serological studies using stored maternal sera or archived dried neonatal blood samples 
have investigated the association between maternal infection and future psychosis 
development among the offspring 
56-64
 (Table 1).  
Table 1. Serologic studies on the association between maternal levels of IgG directed at T. gondii, CMV, 
HSV-1, and -2, Rubella, and Influenza and psychotic disorder among offspring. 
 
All the studies are based on three collections, two American collections of maternal sera from 
pregnant women in the 1960s, and one sample based on dried blood from neonates born in 
Denmark in the 1980s. The focus has been on infections with Toxoplasma gondii, 
cytomegalovirus, herpes simplex virus types 1 and 2 as well as rubella virus (i.e., TORCH-
 
Samples Published 
studies 
 Case definition Type of sample Association with psychotic 
disorder 
National Collaborative 
Perinatal Project 
(NCPP), USA              
Born 1959-1966 
Buka et al., 
2001          
 
2008 
Xiao et al., 
2009 
“Major psychotic 
disorder”, n=27  
 
n=108            
n=120 
Stored 
maternal sera  
T. gondii: t test=0.51 , p=0.61 
CMV:  t test=-0.42, p=0.68 
HSV-1:  t test=-0.57 , p=0.57 
HSV-2:  t test=2.11, p=0.04 
HSV-2:  OR 1.8, 95% CI: 1.1-3.0 
T. gondii: OR 1.3, 95% CI: 0.6-
2.8 
The Prenatal 
Determinants of 
Schizophrenia Study 
(PDS), USA                
Born 1959-67 
Brown et al., 
2005 
                    
2006  
  
“Schizophrenia 
spectrum disorder”, 
n=63    
n=60 
          -”- T. gondii:  OR 2.6, 95% CI: 1.0-
6.8 
 
CMV:  OR 1.1, 95% CI: 0.5-2.4 
HSV-1: OR 1.0, 95% CI: 0.5-2.1 
HSV-2:  OR 1.1, 95% CI: 0.5-2.6 
Danish birth cohort, 
Born since 1981 
Mortensen et 
al., 2007  
                     
2010  
Schizophrenia, 
n=186 
 
 
n=602 
Archived dried 
neonatal blood 
samples 
T. gondii:  OR 1.8, 95% CI: 1.0-
3.2 
HSV-1 and -2: No significant 
association, data not shown 
                   
HSV-2: OR 1.4, 95% CI: 1.0-1.9 
Swedish birth cohort 
Born 1975-85 
Blomström et 
al., 2012 
Schizophrenia,  
n=47 
          -”- T. gondii:  OR 2.0, 95% CI: 0.9-
4.7 
CMV:  OR 2.1, 95% CI: 0.9-4.9 
HSV-1: OR 0.8, 95% CI: 0.4-1.6  
HSV-2: OR 0.5, 95% CI: 0.2-1.4 
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infections) during pregnancy, all of which are known to cause congenital malformations in 
the offspring 
65-67
. 
There are several methodological limitations in these studies. Half of the studies had fairly 
small sample sizes and few exposed cases 
56,59-62
. Moreover, some of the studies used the 
same participants when reporting on exposure to individual pathogens 
57,58,60,61
. It is possible 
that these groups of mothers were exposed to several infections due to related factors such as 
genetic susceptibility and life-style. However, inclusion of such potential confounders was 
limited. Moreover, in serologic studies there is a risk of exposure misclassification when 
exposure status has to be defined in terms of cut-off levels of antibodies. Although 
information on the prevalence of the infectious diseases in the time period and geographic 
area in question would be important, some of the studies from the US did not contain such 
information. Another shortcoming that could complicate comparisons between the studies is 
that psychotic disorders are sometimes included as a mixed group, and sometimes as the 
more restricted diagnosis of schizophrenia. Moreover, the Danish studies had a short follow-
up duration whereby the finding can only be generalized to early onset schizophrenia 
63,64
. 
Overall, the results are contradictory and have limited generalizability. 
In Sweden, rubella vaccination has been part of the national vaccination programme since 
1974 
68
 and apart from isolated outbreaks in specific regions, rubella is very rare in Sweden 
69
. The methods of detecting the highly variable antigenic structure of the different Influenza 
virus strains common between 1975 and 1985 require more blood than eligible from NDBS 
samples. Therefore, the present thesis focused on Toxoplasma gondii, cytomegalovirus, and 
Herpes simplex virus types 1 and 2. Brief information about these pathogens can be found 
below. 
Toxoplasma gondii 
Toxoplasma gondii (T. gondii) is a parasite found in, for example, undercooked meat, poorly 
rinsed vegetables, contaminated water and cat litter. The parasite has a complicated life cycle 
and requires a feline host for the reproductive part of the cycle. Oocysts are excreted in feline 
faeces, whereby humans (or other warm blooded animals) may be infected by the aerosolized 
oocysts as a result of, for example, playing in sandpits, cleaning cat litter trays or ingesting 
the cysts (the latent stage) in undercooked meat. The parasite establishes a lifelong latent 
infection in a slowly replicating bradyzoite stage, hiding inside cysts in cells of the 
intermediate host 
70
. However, in case of immune suppression, e.g., AIDS, it may become 
active again by entering the rapidly replicating tachyzoite stage 
71
. The parasite is distributed 
worldwide with a seroprevalence in the human population of about 30%, although there is a 
variation of between 10-80% 
72
. In Sweden, the seroprevalence is 15-25% among pregnant 
women, decreasing with latitude 
73
. Globally, the incidence rate of congenital toxoplasmosis 
is estimated at 1.5 cases per 1 000 live births 
74
. Congenital toxoplasmosis is very rare in 
Sweden, with a prevalence of 0.73/10 000 births 
73
.  
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The parasite has a preference for the foetal brain and primary infection with T. gondii during 
pregnancy is associated with brain malformation such as microcephaly, enlarged ventricles 
and blindness 
75,76
. However, also asymptomatic congenitally infected children may develop 
sequelae such as cognitive and motor impairments similar to those found in individuals with 
schizophrenia 
77
. 
Cytomegalovirus 
Cytomegalovirus (CMV) is transmitted through body fluids such as saliva, blood, breast 
milk, urine and semen. CMV occurs worldwide but the prevalence varies and in developing 
countries it can be as high as 100% among pregnant women 
78
. In the US the prevalence is 
around 50% 
79
, while in Sweden, the prevalence is around 80% in the adult population 
80
. 
Individuals with CMV have a lifelong latent infection (inactive chronic infection) and may 
become re-infected by other strains 
81
. Similar to T. gondii the chronic infection may re-
activate upon immune deficiency, such as at transplantation, or HIV infection 
82
. Among 
mothers with a chronic infection (preconceptional immunity), transmission of the virus may 
take place from the mother to the foetus either from a primary infection with a new strain of 
the virus, or from reactivation of the chronic infection 
83,84
. The prevalence of congenital 
infection in Europe is low, around 0.2-0.5% 
85
, and about 60% of the infected neonates have 
been infected by mothers with chronic infection 
86
. In about half of all cases of transmission 
to the foetus, maternal primary infection causes clinical symptoms such as brain 
malformation and intrauterine growth restriction, as well as neurodevelopmental sequelae, 
e.g., sensorineural hearing loss, mental retardation and motor impairment 
87
. MRI brain scans 
of children with congenital CMV infection show decreased brain volume in the temporal lobe 
and hippocampus, which resembles that seen in schizophrenia patients 
88,89
. Neonates born to 
mothers with a chronic infection present these symptoms less frequently. However, an 
asymptomatic congenital CMV infection can lead to more subtle cognitive deficits later in 
childhood 
90
.  
Herpes simplex virus type 1 and -2 
Herpes simplex virus type 1 and 2 (HSV-1 and -2) can be sexually transmitted, as well as 
transmitted from body fluids such as saliva. In general, type 1 is the labial variant, and type 2 
the genital variant, but both can occur in either location. After the acute stage, these viruses 
establish latent infections in sensory nerve ganglia 
91
. The prevalence has increased 
worldwide in recent decades and apart from Asia where it is somewhat lower and Africa 
where it is higher, the global prevalence in the adult population is similar to Swedish figures: 
HSV-1 60% and HSV-2 25% 
92,93
. Although transmission from mother to neonate usually 
occurs during delivery 
94
, about 5% of neonates are infected during foetal life 
95
. Apart from 
more common skin and mucus lesions, prenatal infection with Herpes simplex virus can 
cause CNS infection with microcephaly and hydranencephaly 
96
. In particular, infection with 
HSV-2 is associated with mortality and long-term sequelae such as mental retardation and 
cognitive impairments 
97,98
. 
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2.2.1.2 Studies with individual clinical diagnoses 
In addition to studies using sera or blood, register based studies with individual clinical 
diagnoses have explored various groups of maternal infections during pregnancy in relation 
to psychotic disorder in the offspring 
99-103
 (Table 2).  
Similar to the serological studies, most of these register based studies had methodological 
limitations. The studies from the US and Finland had small sample sizes, and few exposed 
cases 
99-101
 an some contained a risk of exposure misclassification 
99,102,103
. In general, all 
studies had a rather short follow-up duration and limitations in the ability to control for 
confounding factors. Overall, associations with respiratory infections, pyelonephritis (boarder 
line significant) and bacterial infection were reported, thus indicating specific effects of 
bacterial infections 
99,101,102
. However, the topic requires further investigation.  
Table 2. Register based studies on the association between maternal infection during pregnancy and 
psychotic disorder among offspring. 
 
Interestingly, both Clarke et al., and Nielsen et al., found synergism between maternal 
psychotic disorder and maternal infection during pregnancy in relation to the risk of 
schizophrenia development in the child 
101,103
. These findings support the theory of gene-
environment interaction in the development of schizophrenia 
8
. 
Nielsen et al., investigated maternal hospital admission with infection before, during and after 
pregnancy as one variable and found that it had an equally strong association with 
schizophrenia in the offspring as infection during pregnancy 
103
. In addition, paternal 
infection before, during and after pregnancy was weakly associated with offspring 
schizophrenia. The authors suggest that a common factor increases the propensity for 
infection and schizophrenia separately rather than a causal effect of the infection per se. 
However, as infection after pregnancy was included the infection may very well have been 
 
Samples Published 
studies 
Exposure Type of 
psychotic 
disorder 
Association with 
psychotic disorder 
The Prenatal 
Determinants of 
Schizophrenia Study 
(PDS), US cohort  
Born 1959-67 
N=7 800 
 
Brown et al., 
2000 
 
Babulas et 
al., 2006 
Respiratory infection 
 
 
Genital/reproductive 
infection                  
(1st trimester) 
 
SSD*, n=58 
 
 
SSD*, n=71 
OR 2.1, 95% CI: 1.0-4.4 
 
 
RR 0.9, 95% CI: 0.2-3.7 
Finnish national cohort  
Born 1947-90    
N=23 400 
 
Clarke et al., 
2009 
Pyelonephritis Schizophrenia, 
n=71 
OR 1.5, 95% CI: 0.9-2.4 
Danish cohort  
Born 1959-61 
N=7 900 
Sorensen et 
al., 2009 
Viral infection 
 
Bacterial infection 
Schizophrenia, 
n=153 
OR 0.5, 95% CI: 0.1-2.1 
 
OR 2.1, 95% CI: 1.1-4.3 
Danish national cohort  
Born 1978-98  
N=1 115 700 
Nielsen et al., 
2013 
Any infection Schizophrenia, 
n=3 700 
RR 1.2, 95% CI: 1.0-1.4 
*Schizophrenia spectrum disorder 
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transmitted to the child 
104,105
. Thus, these results do not exclude a specific effect on the 
foetus due to infection during pregnancy. 
Larger studies with a sufficiently long follow-up to include the majority of cases of 
schizophrenia and assessing them in relation to specific infections, timing of infection and 
interaction with genetic susceptibility to schizophrenia is desirable in order to determine 
underlying biological mechanisms 
13
. 
2.2.2 Infection during childhood 
The theory of exposure to infection affecting the brain during development has subsequently 
evolved to include not only exposure in prenatal life but also during childhood. Brain 
development continues throughout childhood, making it another period that is sensitive to 
disruption 
19
. Until recently, associations between childhood infections and psychotic 
disorder had only been investigated in terms of infections in the central nervous system 
(CNS) 
106-112
 (Table 3).  
Table 3. Cohort studies on the association between clinical diagnosis of CNS infection during childhood 
and psychotic disorder.  
 
Samples Published studies Exposure Type of psychotic 
disorder 
()=exp 
Association with psychotic disorder 
Virus Bacteria 
Finland, 1966-80 
N=11 017  
Rantakallio et al., 
1997 
Koponen et al., 
2004 
CNS infection          
≤14 years  
Schizophrenia, 
n=76 (4) 
Other psychoses, 
n=53 (2) 
Schizophrenia, 
n=100 (4)  
OR 4.8,                 
95% CI: 1.6-14.0 
 
 
 
 
OR 2.5, 
95% CI: 0.9-7.0 
 
 
 
OR=6.8, 
95% CI 1.4-32.8 
 
Britain, 1958  
N=17 414 
 
Leask et al.,   
2002 
“Common 
childhood 
illness” 
Meningitis ≤12 y 
 
“Narrow 
schizophrenia”  
n=35 (1) 
 
OR= 7.8, 
95% CI 1.0-59.0 
 
Finland, 1960-91   
N=320 
Suvasaari 
 et al., 2003 
CNS infection  
≤14 years 
 
Schizophrenia,  
n=3 (exp)  
CI=0.94% 
(Cumulative 
Incidence) 
 
Brazil, 1971-74 
N=346 
 
Abrahao et al., 
2005 
sibling controls  
 
Meningococcal 
meningitis  
≤4 years 
Schizophrenia  
n=8 (8) 
Other psychosis   
n=25 (21) 
 4.2% vs 0% 
 
12.1% vs 2.8% 
 
Sweden, 1973-85  
N=1 187 553 
 
Dalman et al., 
2008 
 
CNS infection 
≤12 years 
 
Non-affective 
psychosis 
n=2 269 (23) 
         
Schizophrenia (8) 
 
RR=1.3, 
95% CI: 0.8-2.0 
  
 
RR=1.6 
95% CI: 1.0-2.5 
RR=0.9, 
95% CI: 0.3-2.4 
  
 
RR=0.9 
95% CI 0.4-2.5 
Israel, 1970-87  
N=9 970 
 
Weiser et al., 
2010 
Gastroenteritis 
controls 
CNS infection 
≤15 years 
 
Schizophrenia 
n=72 (24) 
 
HR=0.7 
95% CI: 0.4-1.2 
 
HR=1.7  
95% CI: 0.7-4.1 
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Most of these studies have methodological limitations. For example, four of the studies had 
between one and four exposed cases 
106-109
, while Weiser et al., used controls with another 
type of infection, which may have diluted the results 
112
. Abrahao et al., had a huge loss to 
follow-up of 96% 
110
. All studies also had a short-term follow up.  
In a meta-analyses conducted by Khandaker et al., only two of the studies presented in Table 
3 were included in the analyses due to methodological limitations 
107,111
. A significant 
association between childhood CNS infection and non-affective psychosis was reported, with 
a pooled risk ratio of 1.6. Differentiation between bacteria and virus indicated that the 
association was driven by viral CNS infections. However, the two studies included had a 
relatively short follow-up duration and small sample sizes. 
Recently, infections other than CNS before the age of three years were reported to increase 
the risk of schizophrenia in a male cohort from Australia 
113
. Considering these observations, 
any infection during childhood, CNS or non-CNS, could imply a risk of psychotic disorder, 
but has not been sufficiently investigated.  
Altogether, no large studies with a long-term follow-up, that investigate the effect of any as 
well as specific infections during childhood have been made. In addition, a temporal 
association between childhood infection and psychotic disorder is lacking. 
2.2.3 The “two-hit” model 
The “two-hit” model hypothesizes a genetic “first hit” with mutations in schizophrenia 
candidate genes involved in brain development and a “second hit” further affecting the 
function of these genes, which subsequently leads to the development of psychotic disorder 
114
. A number of stressors including infection has been suggested, but more research is 
necessary to confirm the hypothesis 
115
. In agreement with the two-hit model, an insult on the 
developing brain during foetal life in terms of immune activation or infection could induce an 
increased vulnerability to a second hit 
116
. Immune alterations have in fact been observed in 
individuals who subsequently develop schizophrenia 
117,118
.  In addition, maternal infection 
during pregnancy may alter the infants immune response,  an effect of which can increase the 
susceptibility and vulnerability to infection for years 
119
. Despite these facts, no study to date 
has examined interaction between maternal infection during pregnancy and infection during 
childhood in the risk of developing non-affective psychosis. 
2.2.4 Infection during foetal life and childhood – what does it implicate? 
Exposure to infection can involve risks due to common mechanisms and not the pathogen per 
se. Hypotheses on the underlying factors associated with infection are presented below. 
2.2.4.1 Maternal immune activation (MIA) and inflammation 
Immune activation including inflammation is part of the host response to infection, by which 
cellular and humoral mechanisms attempt to contain and eliminate the pathogen.  
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In 1997 Gilmore and Jarskog proposed that pro-inflammatory cytokines might be involved in 
the causal pathway of psychosis development 
120
. Importantly, cytokines can pass over the 
placenta, and cross the blood-brain barrier 
121-123
. However, so far the clinical support for an 
association between maternal immune activation (MIA) and schizophrenia development in 
the offspring is fairly weak. In terms of cytokines as a risk factor, two case-control studies, 
one using maternal second trimester sera and the other third trimester sera, found associations 
with IL- 8 and TNF-α, respectively, but not with other cytokines, and were unable to replicate 
each other’s results 124,125. More recently, Nielsen et al., analysed a number of inflammatory 
markers, including the aforementioned, from neonatal blood and found no associations 
126
. 
Two other studies support the role of MIA, due to findings that neonates of mothers with 
increased levels of activated C1q (the initiator molecule of the complement cascade) 
respectively the APP CRP have a higher risk of developing psychotic disorder 
127,128
. In 
contrast, a large number of experimental studies in pregnant rodents support the role of MIA 
in the development of psychosis-related behaviours 
17,129
.  
There are over seventy cytokines involved in cell-signaling with a broad range of specific and 
overlapping functions. The action of cytokines is highly dependent on specific receptors 
located on the cell itself (autocrine signaling), neighbouring cells (paracrine signalling), or 
distant cells reached via the circulation (endocrine signalling) 
130
. Consequently, it is difficult 
to fully understand and interpret results from snapshot analyses of cytokine levels. However, 
given that MIA is an important player in psychosis development, associations between any 
severe infections during pregnancy and non-affective psychosis should be observed.  
2.2.4.2 Deficient immune response 
Another interpretation of the association between schizophrenia and various infections 
concerns a deficient immune response 
131,132
. In fact, patients with schizophrenia suffer more 
frequent infections compared to controls 
133,134
. More importantly, infection as a cause of 
death is much higher among patients with schizophrenia than the general population 
135-137
, 
indicating a vulnerability to such exposure. However, these associations may be biased by 
life-style factors (e.g., obesity, drugs) and delayed healthcare contact 
138
. There are two 
studies that provide clinical support for a deficient innate immune response among 
individuals with psychotic disorder. In an experimental study Müller et al., demonstrated that 
monocytes (white blood cells) obtained from schizophrenia patients had a decreased in vitro 
response to viral and bacterial components compared to such cells obtained from controls 
118
. 
Gardner et al., measured levels of acute phase proteins (APP) in neonatal blood and found 
that neonates who later develop non-affective psychosis had lower levels of some APPs 
compared to controls 
117
. APPs are serum proteins that form part of the innate immune 
response (the first line defense). Upon infection/inflammation their release is triggered by 
cytokines. They are involved in many steps of the inflammatory response, as well as in 
coagulation and transport. Similar to cytokines, their regulation is complex with an additive, 
inhibitory, and synergistic effect on each other 
139
. However, in contrast to cytokines, these 
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proteins fluctuate more slowly and can remain elevated for long periods of time following an 
infection. Hence, altered levels of APPs are much more likely to be captured.  
Relevant to this thesis is the fact that both cytokines and acute phase proteins are peripherally 
acting immune proteins involved in protection against infection as well as in the cross-talk 
between the immune system and the CNS. In addition, they are involved in the formation and 
plasticity of the developing brain 
122,140
. Thus, they could be part of the pathway between 
infection and psychotic disorder 
141
. In this regard, altered immunity in the aetiology of 
schizophrenia has been proposed 
131
. Nevertheless, interaction between maternal infection 
during pregnancy and neonatal immune activity in the development of psychotic disorder has 
not been investigated.  
2.2.4.3 Affected microbiom - antibiotics 
It is well known that there is communication between the microbiom, the gut, and the brain 
142
. It is also becoming increasingly evident that the composition of the microbes colonizing 
the gut plays an important role in brain function and brain development as reviewed in 
143
, 
while it has also been suggested that the microbiom plays a role in the aetiology of 
neurodevelopmental disorders 
144
. Indeed, Heijitz et al., demonstrated in a mouse model that 
the microbiom affects the level of DA in the brain 
145
; mice with a sterile gut (without a 
“normal” microbiom) had an elevated DA and behaved hyperactively compared to mice with 
“normal” gut flora. Presumably, all individuals with severe bacterial infections (e.g., treated 
in hospital) receive antibiotics, which inevitably alter the microbiom in the gut to a greater or 
lesser degree and may thus have implications for neurodevelopmental disorders such as 
schizophrenia. Only one study has reported bacterial infection during pregnancy to be 
associated with schizophrenia in the offspring. No study has investigated bacterial infection 
during childhood other than in the CNS and risk of psychotic disorder. This subject needs 
further attention. 
2.2.4.4 Genetic susceptibility 
As mentioned previously, GWAS have identified common genetic variants (SNPs) associated 
with schizophrenia. Some of these are located within genes that are also connected with 
infection. In particular, common variants in a region within a large gene on chromosome 6, 
which encode the major histocompatibility complex (MHC), have been reported to be 
associated with schizophrenia 
5,146
. MHC is a molecule responsible for anti-gene presentation 
to T lymphocytes and essential in the response to infection. More recently, interactions 
between SNPs in the MHC region and maternal CMV and HSV-1 infection in schizophrenia 
risk have been reported 
147,148
. Additionally, GWAS has reported on interactions with other 
genetic variations and maternal exposure to T. gondii and CMV 
147,149
. Thus, analyses of 
interactions between genetic susceptibility and infection (both specific infections and 
infection in general) early in life in the risk of developing psychotic disorder need further 
investigation. 
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2.3 SUMMARY 
Numerous studies have addressed the effect of infection during foetal life and childhood on 
the risk of developing psychotic disorder. However, contradictory findings, methodological 
limitations, and knowledge gaps highlight the need for further attention on the subject. In 
order to increase consistency and disentangle the mechanisms by which early infection may 
be involved in the development of psychotic disorder, it is essential to:  
 Conduct large studies with a sufficiently long follow-up to include the peak incidence 
of schizophrenia.  
 Have good control of factors that may confound the association between early 
infection and psychosis.  
 Scrutinize the association with any infection and with individual infections during 
both foetal life and childhood. 
 Investigate the relation between maternal infection during pregnancy and neonatal 
immune responses and subsequent psychosis development.  
 Disentangle whether there is susceptibility for infection and for psychosis separately 
or rather a specific effect by the infection per se.       
 Explore the risks of multiple hits of infection. 
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3 AIMS OF THE THESIS 
The overall aim of this thesis was to investigate the association between infection during fetal 
life and childhood and non-affective psychosis later in life.  
For that purpose, four studies were designed using health care registers and biological 
samples, addressing the following research questions: 
 
Study I Is maternal chronic infection with the neurotropic pathogens Toxoplasma 
gondii, cytomegalovirus, herpes simplex virus type-1, and -2 associated with schizophrenia or 
other non-affective psychoses in the offspring? 
  
Study II Does maternal chronic infection with Toxoplasma gondii, cytomegalovirus, 
herpes simplex virus type-1, and -2 during pregnancy influence the immune activity in terms 
of levels of acute phase proteins in the neonate? Is the psychosis risk associated with maternal 
chronic infection dependent of the immune response in the neonate? 
  
Study III Are childhood infections associated with non-affective psychosis later in life? Is 
the risk associated with all types of infection, or rather specific for certain groups of 
pathogens (bacteria or virus)? Is the timing and the number of infections of importance? 
  
Study IV Is maternal infection during pregnancy associated with non-affective psychosis 
in the offspring? Are parental psychiatric disorder (as a marker of genetic vulnerability) and 
parental infections prior to or during pregnancy acting synergistically in the development of 
psychosis among the offspring? Is maternal infection during pregnancy associated with 
infections during childhood, and do their combined effect increase the risk of developing 
non-affective psychosis (risk of multiple hits)? 
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4 MATERIAL AND METHODS 
Figure 2 illustrates the research questions and the data sources, and the relationship between 
the four studies included in the thesis. 
4.1 REGISTERS AND BIO-BANKS 
The studies in the thesis are based on linkages to several registers held by Statistics Sweden 
and the National Board of Health and Welfare.  
The National Patient Register (NPR)  includes virtually all psychiatric inpatient care in 
Sweden since 1973, and outpatient care since 2005 
150
. Somatic inpatient care is completely 
covered from 1987, but most county councils are included since 1978. The NPR was used to 
find data regarding any hospital admission including the diagnoses of infection or non-
affective psychoses.  
The Medical Birth Register (MBR) was initiated in 1973 and includes data from the prenatal, 
delivery and neonatal periods from about all deliveries in Sweden 
151
. Data on gestational age 
and obstetric complications were retrieved from the MBR. 
The Population and Housing Censuses (PHC) were administered every five years between 
1960 and 1990 and included, by law, all individuals registered and living in Sweden with 
information on demographic data 
152
. Data on socio-economic status in terms of single 
household, parental employment, and household receiving social welfare benefits was 
obtained from the PHC of 1985 and 1990.  
The Longitudinal Integration Database for Health Insurance and Labour market studies 
(LISA) is updated annually since 1990 with a new annual register 
152
. The database includes 
all individuals 16 years of age and older registered in Sweden as of December 31 for each 
year. The LISA integrates existing data from the labour market, educational and social 
sectors, and connects family members.  Data on socio-economic status in terms of disposable 
income in the family, and education level among the parents were obtained from the LISA. 
The Total Population Register (TPR) was initiated 1968 
152
. This register includes the entire 
Swedish population and is the basis for all official population statistics. Information such as 
civil status, place of residence, country of birth, and relations between family members is 
available. Data on year of migration among parents was retrieved from the TPR. 
The Income and Taxation Register (ITR) includes information of income, pensions, and taxes 
among all individuals registered in Sweden, since 1968 
152
. Data on social welfare benefits 
was retrieved from this register. 
The Multi-Generation Register (MGR) consists of individuals born 1932 or later who have 
been registered in Sweden at any time since 1961
152
. The register includes information of 
biological and adoptive parents. Data on biological fathers was obtained from the MGR. 
 26 
 
 
 
 
Is
 m
at
er
n
a
l 
ch
ro
n
ic
 i
n
fe
ct
io
n
 w
it
h
 t
h
e 
n
eu
ro
tr
o
p
ic
 p
at
h
o
g
en
s 
T
o
xo
p
la
sm
a
 g
o
n
d
ii
, 
c
y
to
m
e
g
al
o
v
ir
u
s,
 h
er
p
es
 s
im
p
le
x
 v
ir
u
s 
ty
p
e
-
1
, 
an
d
 -
2
 a
ss
o
ci
at
ed
 w
it
h
 s
ch
iz
o
p
h
re
n
ia
 o
r 
o
th
er
 n
o
n
-a
ff
ec
ti
v
e 
p
sy
c
h
o
se
s 
in
 t
h
e 
o
ff
sp
ri
n
g
?
 
A
re
 c
h
il
d
h
o
o
d
 i
n
fe
c
ti
o
n
s 
as
so
ci
at
ed
 w
it
h
 
n
o
n
-a
ff
ec
ti
v
e 
p
sy
ch
o
si
s 
la
te
r 
in
 l
if
e?
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Is
 t
h
e 
ri
sk
 a
ss
o
ci
at
ed
 w
it
h
 a
ll
 t
y
p
e
s 
o
f 
in
fe
ct
io
n
, 
o
r 
ra
th
er
 s
p
ec
if
ic
 f
o
r 
ce
rt
ai
n
 
g
ro
u
p
s 
o
f 
p
at
h
o
g
en
s 
(b
ac
te
ri
a 
o
r 
v
ir
u
s)
?
  
  
 
Is
 t
h
e 
ti
m
in
g
 a
n
d
 t
h
e 
n
u
m
b
er
 o
f 
in
fe
ct
io
n
 o
f 
im
p
o
rt
an
ce
?
 
D
o
es
 m
at
er
n
a
l 
ch
ro
n
ic
 i
n
fe
ct
io
n
 w
it
h
 
T
o
xo
p
la
sm
a
 g
o
n
d
ii
, 
cy
to
m
e
g
a
lo
v
ir
u
s,
 
h
er
p
es
 s
im
p
le
x
 v
ir
u
s 
ty
p
e
-1
, 
an
d
 -
2
 d
u
ri
n
g
 
p
re
g
n
an
c
y
 i
n
fl
u
e
n
ce
 t
h
e 
im
m
u
n
e 
ac
ti
v
it
y
 i
n
 
te
rm
s 
o
f 
le
v
el
s 
o
f 
ac
u
te
 p
h
as
e 
p
ro
te
in
s 
in
 t
h
e 
n
eo
n
at
e?
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Is
 t
h
e 
p
sy
c
h
o
si
s 
ri
sk
 a
ss
o
ci
at
e
d
 w
it
h
 
m
at
er
n
a
l 
ch
ro
n
ic
 i
n
fe
ct
io
n
 d
ep
en
d
en
t 
o
f 
th
e 
im
m
u
n
e 
re
sp
o
n
se
 i
n
 t
h
e 
n
eo
n
a
te
?
 
Is
 m
at
er
n
a
l 
in
fe
ct
io
n
 d
u
ri
n
g
 p
re
g
n
a
n
c
y
 
as
so
ci
at
ed
 w
it
h
 n
o
n
-a
ff
ec
ti
v
e 
p
sy
ch
o
si
s 
in
 
th
e 
o
ff
sp
ri
n
g
?
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
A
re
 p
ar
en
ta
l 
p
sy
ch
ia
tr
ic
 d
is
o
rd
er
 a
n
d
 
p
ar
en
ta
l 
in
fe
ct
io
n
s 
p
ri
o
r 
to
 o
r 
d
u
ri
n
g
 
p
re
g
n
an
c
y
 a
ct
in
g
 s
y
n
er
g
is
ti
ca
ll
y
 i
n
 t
h
e 
d
ev
el
o
p
m
en
t 
o
f 
p
sy
c
h
o
si
s 
a
m
o
n
g
 t
h
e 
o
ff
sp
ri
n
g
?
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Is
 m
at
er
n
a
l 
in
fe
ct
io
n
 d
u
ri
n
g
 p
re
g
n
a
n
c
y
 
as
so
ci
at
ed
 w
it
h
 i
n
fe
ct
io
n
s 
d
u
ri
n
g
 c
h
il
d
h
o
o
d
, 
an
d
 d
o
 t
h
ei
r 
co
m
b
in
ed
 e
ff
ec
ts
 i
n
cr
ea
se
 t
h
e 
ri
sk
 o
f 
d
ev
e
lo
p
in
g
 n
o
n
-a
ff
ec
ti
v
e 
p
sy
c
h
o
si
s?
 
I II
 
II
I 
IV
 
R
es
ea
rc
h
 q
u
es
ti
o
n
s 
S
tu
d
ie
s 
D
at
a 
so
u
rc
es
 
M
at
er
n
al
 i
n
fe
ct
io
n
 d
u
ri
n
g
 
p
re
g
n
an
c
y
 
In
fe
ct
io
n
 d
u
ri
n
g
  
 
ch
il
d
h
o
o
d
 
In
d
iv
id
u
a
ls
 b
o
rn
 i
n
 S
w
ed
en
 b
et
w
ee
n
 1
9
7
5
 
an
d
 1
9
8
5
 w
it
h
 d
at
a 
o
f 
n
o
n
-a
ff
ec
ti
v
e 
p
sy
ch
o
si
s 
b
et
w
ee
n
 1
9
8
7
 a
n
d
 2
0
0
3
 i
n
 t
h
e 
N
at
io
n
al
 P
at
ie
n
t 
R
eg
is
te
r 
an
d
 i
n
 P
sy
k
ia
tr
is
k
t 
V
år
d
 S
y
st
e
m
 w
er
e 
id
en
ti
fi
ed
 (
ca
se
s)
. 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Ig
G
 l
ev
el
s 
(a
n
d
 A
P
P
 l
ev
el
s 
fo
r 
st
u
d
y
 I
II
) 
w
er
e 
m
ea
su
re
d
 i
n
 N
D
B
S
 f
ro
m
 1
9
8
 c
as
es
 
an
d
 5
2
4
 m
at
c
h
ed
 c
o
n
tr
o
ls
. 
T
h
e 
N
D
B
S
 w
er
e 
co
ll
ec
te
d
 f
ro
m
 t
h
e 
n
at
io
n
a
l 
b
io
b
an
k
 a
t 
K
ar
o
li
n
sk
a 
U
n
iv
er
si
ty
 H
o
sp
it
a
l,
 S
o
ln
a 
  
  
  
  
  
  
  
 
A
ll
 i
n
d
iv
id
u
al
s 
b
o
rn
 i
n
 S
w
ed
e
n
 b
et
w
ee
n
 
1
9
7
3
 a
n
d
 1
9
8
5
w
er
e 
in
cl
u
d
ed
. 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
1
 1
7
2
 8
7
9
 w
er
e 
fo
ll
o
w
ed
 u
p
 o
n
 d
ia
g
n
o
si
s 
o
f 
n
o
n
-a
ff
ec
ti
v
e 
p
sy
ch
o
si
s 
in
 t
h
e 
N
at
io
n
al
 
P
at
ie
n
t 
R
e
g
is
te
r 
fr
o
m
 1
4
 y
ea
rs
 o
f 
ag
e 
u
n
ti
l 
2
0
0
6
. 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
4
 6
3
8
 h
ad
 a
 d
ia
g
n
o
si
s 
o
f 
n
o
n
-a
ff
ec
ti
v
e 
p
sy
ch
o
si
s.
 
A
ll
 i
n
d
iv
id
u
al
s 
b
o
rn
 i
n
 S
w
ed
e
n
 b
et
w
ee
n
 
1
9
7
8
 a
n
d
 1
9
9
7
 a
n
d
 t
h
ei
r 
m
o
th
er
s 
w
er
e 
in
cl
u
d
ed
. 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
1
 9
7
1
 6
2
3
 w
er
e 
fo
ll
o
w
ed
 u
p
 o
n
 d
ia
g
n
o
si
s 
o
f 
n
o
n
-a
ff
ec
ti
v
e 
p
sy
ch
o
si
s 
in
 t
h
e 
N
at
io
n
al
 
P
at
ie
n
t 
R
e
g
is
te
r 
fr
o
m
 1
4
 y
ea
rs
 o
f 
ag
e 
u
n
ti
l 
2
0
1
1
. 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
8
 3
3
0
 h
ad
 a
 d
ia
g
n
o
si
s 
o
f 
n
o
n
-a
ff
ec
ti
v
e 
p
sy
ch
o
si
s.
 
F
ig
u
re
 2
. 
O
v
er
v
ie
w
 o
f 
th
e 
re
se
a
rc
h
 q
u
es
ti
o
n
s,
 s
tu
d
ie
s 
a
n
d
 d
a
ta
 s
o
u
rc
es
 i
n
cl
u
d
ed
 i
n
 t
h
e 
th
es
is
. 
  27 
Psykiatriskt Vård System (PVS) was a local psychiatric outpatient care register used in 
Stockholm County Council between 1997 and 2006 
28
. PVS had a 80% coverage and was 
unique in that it registered diagnoses (both DSM and ICD) and not only visits.   
In Sweden, since 1975, blood is collected from all newborns in a screening program for early 
detection of diseases such as PhenylKetonUria (PKU), and archived on filter paper in a 
biobank at Karolinska University Hospital, Solna. These neonatal dried blood spots (NDBS) 
were used for analyzing maternal exposure to infection in terms of antibody levels and 
neonatal immune reactivity in terms of levels of acute phase proteins (APPs). 
4.2 STUDY SAMPLES 
Study I and II     All individuals born in Sweden between 1975 and 1985 and treated as in- or 
outpatients in Stockholm County Council until 2004 were included. The participants had to 
be alive and resident in Sweden on December 31, 2003. Written informed consent was 
obligate for enrollment in the study. 
Study III     All individuals born in Sweden between 1973 and 1985, and resident in Sweden 
at 14 years of age were included in the study and followed up until end of 2006. Adopted 
individuals and individuals who emigrated before 14 years of age were excluded.    
Study IV     All individuals born in Sweden between 1978 and 1997, with information on 
biological father were included and followed up from 14 years of age until end of 2011.  
4.3 MEASURES 
4.3.1 Exposure 
The measure of prenatal and childhood exposure to infections varied in the four studies. 
Study I As mentioned previously, serology is an efficient method of determining 
microbial exposure, and was therefore used in this thesis. Maternal exposure to chronic 
infection was measured as levels of maternal immunoglobulin G (IgG) antibodies towards the 
infectious agents T. gondii, CMV, HSV-1, and -2 in NDBS. Neonatal blood harbors maternal 
IgG antibodies predominately derived from the maternal circulation and are transferred 
during pregnancy, reviewed in 
55
. Therefore, neonatal blood explores maternal infection or 
immune reactivity at some point prior to delivery. 
Study II Previously obtained data on maternal exposure to the infectious agents T. 
gondii, CMV, HSV-1, and -2 (See study I) and on neonatal immune activity in terms of levels 
of APPs measured from the same blood spots 
117
 were used. APPs are part of the innate 
immunity and are produced in response to inflammatory cytokines 
153
. In general, APPs are 
not transported across the placenta and thus provide a measure of the activity of the innate 
immune response in the neonate 
154
. 
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Study III Information on primary diagnoses of infection during childhood was retrieved 
from the NPR. All diagnoses arising from infection was identified in ICD-8, -9 and -10, 
(Supplementary table S1(Table S1)). 
Study IV Information on diagnoses of maternal infection before and during pregnancy, 
and infection during childhood was retrieved from NPR. As before, all diagnoses of infection 
was identified in ICD-8, -9 and -10, (Table S1). Mainly the primary diagnosis was retrieved. 
However, in those cases the primary diagnosis was of obstetric origin the first diagnosis of 
infection of the seven secondary diagnoses was extracted.  
4.3.2 Outcome 
Non-affective psychoses were defined according to the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DSM-IV) and International Classification of Disease 
(ICD-9 and -10) as follows: DSM-IV: 295.1-.4, .6, .9 Schizophrenia, 295.7 Schizoaffective 
disorders, 297.1 Persistent delusional disorders, 297.3 Induced delusional disorder, 298.8 
Acute and transient psychotic disorders, 298.9 Unspecified nonorganic psychosis and 301.22 
Schizotypal disorder; ICD-9 295A-E, G, W and X Schizophrenia, 295F Schizotypal disorder, 
297B, C, W and X, Persistent delusional disorders, 297D Induced delusional disorder, 295H 
Schizoaffective disorders and 298C and E Acute and transient psychotic disorders, 298W 
Other nonorganic psychotic disorders, 298X Unspecified nonorganic psychosis. Other 
nonorganic psychoses excluding depressive type psychosis and excitative type psychosis; 
ICD-10: F20 Schizophrenia, F21 Schizotypal disorder, F22 Persistent delusional disorders, 
F23 Acute and transient psychotic disorders, F24 Induced delusional disorder, F25 
Schizoaffective disorders, F28 Other nonorganic psychotic disorders, F29 Unspecified 
nonorganic psychosis.  
The more narrow diagnosis of schizophrenia was defined as DSM-IV: 295.1-.4, .6, .9 
Schizophrenia; ICD-9 295A-D, G, W and X Schizophrenia; ICD-10: F20 Schizophrenia. 
4.4 BLOOD SPOT ANALYSES 
As part of a neonatal screening program for metabolic diseases, blood from all newborns in 
Sweden has been collected on filter papers since 1975, and stored at 4°C at a central biobank. 
Antibodies in filter paper blood spots that have been stored for as much as two decades are 
stable 
155,156
. Half a blood spot from each participant was excised and transferred to a small 
plastic ziploc bag that received an identification number. During processing, all personnel 
were blind to case-control status of the filters.  
Study I A disc, 3.2 mm in diameter, was cut from each blood spot and distributed into 
deep 96-well plates sealed with AxyMat, Axygen scientific Inc (Union City, CA, USA). Each 
plate included blank wells that were empty or contained a disc without blood. Blood was 
eluted from the filter paper by incubation with 100 μl of phosphate buffered saline (PBS). 
Levels of IgG antibodies directed at infectious agents in the eluates were measured by 
Enzyme-Linked Immuno Sorbent Assay method (ELISA). Anti CMV and T. gondii IgG were 
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measured by assays from Vitro-Immun Labor Diagnostika GmbH (Oberursel, Germany) and 
anti HSV-1 and -2 IgG by assays from Focus Diagnostics Inc (Cypress, CA, USA).  
Study II Apart from using the aforementioned IgG data, analyses of APP concentration 
were performed. Another 3.2 mm diameter disc was punched from each blood spot and 
immersed in 80 μL of PBS containing 1% bovine serum albumin and 0.05% Tween for 
elution. Eluates were analyzed for the concentration of nine APP using a premixed, magnetic 
bead-based multiplex panel from Bio-Rad Laboratories Inc (Hercules, CA, USA). 
Concentrations of the APPs were imputed using Bio-Plex 200 Suspension Array System with 
Bio-Plex Manager 6.0 software. All personnel were blind to case-control status of the filters 
during the processing. 
4.5 STATISTICAL ANALYSES 
Study I The main association investigated was the relation between maternal exposure 
to the infectious agents and schizophrenia respectively other non-affective psychosis. 
Exposure status was based on age weighted prevalences for the four pathogens among 
pregnant women during the years 1975-1985, and was for T. gondii 25%, CMV 75%, HSV-1 
60%, and for HSV-2 25%. The distributions among control subjects were used to find the 
cut-off value (the plate normalized optical density value) that corresponded to each of these 
percentiles allowing maternal IgG levels to be analyzed as dichotomous variables. Antibody 
levels between 75
th
 and 90
th
 percentiles, and above the 90
th
 percentile for T. gondii and 
between 25
th
 and 50
th 
percentiles, 51
st
 and 75
th 
percentiles, and above the 75
th
 percentile for 
CMV were also investigated. Odds ratios (OR) and 95% confidence intervals (CI) were 
calculated by using conditional logistic regression model for matched data. All statistical 
analyses were made with The SAS software package, Version 9.1 (SAS Institute, Inc., Cary, 
N.C.). 
Study II To explore whether maternal chronic infection with T. gondii, CMV, HSV-1, 
and -2 during pregnancy influence the immune activity in the neonate, median levels of the 
nine APPs were compared between exposed and unexposed individuals for each of the 
infectious agents, for controls and cases (non-affective psychosis) separately. As in study I, 
maternal exposure status was based on the expected age-weighted prevalences among 
pregnant women in Stockholm during the years 1975-1985: T. gondii 25%, CMV 75%, HSV-
1 60% and HSV-2 25%. Then the distributions among control subjects were used to find the 
optical density value (the cut-off value) corresponding to each of these percentiles allowing 
maternal IgG levels to be analyzed as dichotomous variables. The distribution of APP 
concentrations was skewed whereby Mann-Whitney U test (M-W) were chosen to calculate 
p-values of the difference of the median between the two groups (exposed and unexposed). 
To estimate the effect of maternal exposure and neonatal APP levels on psychosis risk, 
conditional logistic regression was used to calculate OR and 95% CI.  Individuals were 
classified as either exposed or unexposed to microbial agent (as above) and as having either 
low APP levels (those in the lowest tertile) or high APP levels (those in the middle and 
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highest tertiles), again established using the distribution of each APP among controls. The 
reference was unexposed individuals with high APP levels.  
To avoid problems with multiple comparisons and to have a marker of innate immune 
response we used Principal Components Analysis (PCA) to create an APP score. Information 
from the nine inter-correlated APPs were collapsed into a single score for each person 
117
. 
Individuals were classified as having either a low APP score (having an APP score below the 
median) or a high APP score (APP score above the median).  
Departure from additivity implicates biological interaction 
157
. In other words, biological 
interaction occurs when the combined effect of two factors is greater than the sum of their 
individual effect. The relative access risk due to interaction (RERI) can be used to measure 
departure from additivity using multiplicative models such as logistic regression or cox 
regression 
158
. To identify interaction between low levels of the different APPs and maternal 
exposure to T. gondii respectively CMV in the risk of developing non-affective psychosis or 
schizophrenia we quantified the relative excess risk due to interaction (RERI). RERI was 
defined as: RERI = RR₁₁ - RR₁₀ - RR₀₁ + 1, assuming that the matched OR can be used 
alternately of the relative risk (RR). The reference category was defined as those unexposed 
to both risk factors, i.e., RR₀₀ = 1. RERI = 0 indicates no interaction. Analyses were made 
with the IBM SPSS statistics 22.0 (IBM, Armonk, NY, USA). 
Study III The main association investigated was the relationship between hospital 
admission with infection during childhood (0-13 years of age), and non-affective psychosis 
later in life. Hazard ratios (HR) with 95% CI were estimated using Cox proportional hazards 
models of time in the study, with non-affective psychosis as the outcome. Time in the study 
was calculated from the starting date, which was from 14 years of age, until the first hospital 
admission with non-affective psychosis, date of death, date of emigration, or 31 December 
2006, whichever came first. 
In addition, to explore the effect of exposure at various ages timing of exposure were divided 
into four different age periods: first year, 1-3, 5-9, and 10-13 years. To explore if the risk is 
particular the diagnoses of infection were subdivided into bacterial, viral, and other infection 
(“other infection” included all non-bacterial and non-viral infections, and unknown or not 
specified infection), and into CNS and non-CNS infections. Next, we investigated whether 
the risk of developing non-affective psychosis increased with number of admission with 
infection during childhood. Additionally, to decide what confounders should be included in 
the analyses, their associations with the exposure were estimated using logistic regression to 
calculate OR and 95% CI. Associations between confounders and outcome were calculated 
by Cox regression (see above). All analyses were made with IBM SPSS statistics 22.0 (IBM, 
Armonk, NY, USA).  
Study IV Children were followed from 14 years of age until first diagnosis of non-
affective psychosis, date of death, date of emigration, or 31 December 2011, whichever came 
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first. Associations between parental hospital admission with infection prior to or during 
pregnancy and offspring non-affective psychosis were calculated as HR and 95% CI by using 
the Cox regression model. Pregnancy was defined as first day of last menstrual period (LMP) 
before pregnancy up until the day of delivery. Trimesters were defined as: 0
 th
: LMP-35days 
(before uteroplacental circulation is established), 1
st
: 36-97 days, 2
nd
: 98-188 days, and 3
rd
: 
189 days-delivery. Associations between maternal infection during pregnancy and childhood 
infection among offspring were calculated with OR and 95% CI by using logistic regression 
model. To test for biological interaction between parental infection prior to or during 
pregnancy and parental psychiatric disorders in the risk of developing non-affective 
psychosis, the RERI was calculated. Likewise, the RERI was calculated to identify possible 
interaction between maternal infections prior to or during pregnancy and childhood infections 
in the development of non-affective psychosis. Statistical analyses were made using IBM 
SPSS statistics 22.0 (IBM, Armonk, NY, USA). 
In all the studies, multiple confounding factors were included in the analyses. These are 
described in the Methodological consideration section. 
4.6 ETHICAL APPROVALS 
Ethical approval has been sought and granted from the Regional Ethics Committee of 
Stockholm, EPN. Paper I, and II: Dnr 03-029 and Paper III, IV: Dnr 2010/1185-31/5. Written 
informed consent from the participants was required for collection of the neonatal blood 
samples.  
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5 RESULTS 
5.1 STUDY I 
Blood spots from 198 cases and 524 matched controls were collected. Maternal exposure to 
T. gondii, and CMV were associated with schizophrenia (Figure 3), but not with other non-
affective psychoses OR 0.8, 95% CI: 0.5, 1.2 respectively OR 1.0, 95% CI: 0.6, 1.5. 
Adjustments for maternal migration and age ≥35 had no major influence on these estimates. 
Maternal exposures to herpes virus -1 or -2 were neither associated with schizophrenia 
(Figure 3) nor with other non-affective psychoses OR 1.0, 95% CI: 0.7, 1.5 respectively OR 
1.3, 95% CI 0.9, 2.1. 
 
 
 
 
 
 
 
 
 
Figure 3. OR and 95% CI of schizophrenia, ICD-10 F20 in relation to levels of IgG directed at T. 
gondii, CMV, HSV-1, and -2. (Study I) 
Maternal exposure to T. gondii >90
th
 percentile, was associated with a three times higher 
relative risk of developing schizophrenia than those within the reference range, OR 3.2, 95% 
CI: 1.0, 9.8. Also CMV antibodies at higher levels (>75
th
 percentile) indicated an increased 
relative risk OR 2.7, 95% CI: 0.9, 8.2. There was no covariance between T. gondii and CMV, 
indicating an independent association with schizophrenia. 
5.2 STUDY II 
Acute phase protein levels across maternal exposures among neonates who will not develop 
psychotic disorder  
Children born to mothers with serological evidence of T. gondii or CMV exposure had 
significantly higher levels of each of the nine different APPs in NDBS, and the APP-score 
were significantly higher as compared to children born to unexposed mothers. There was one 
exception; the CRP level among CMV exposed mothers did not reach statistical difference in 
levels as compared to unexposed mothers (Table 4). Maternal exposure to HSV-1 or -2 was 
not associated with any of the neonatal APP levels (Table S2). 
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Acute phase protein levels across maternal exposures among neonates who will develop 
psychotic disorder 
Levels of the different APPs or APP scores among individuals who later developed non-
affective psychosis or the more restricted diagnosis of schizophrenia did not significantly 
vary according to maternal exposure to T. gondii and CMV (Table 4), or HSV-1 and -2 
(Table S2). 
Synergistic effect 
Among neonates with high APP levels did maternal T. gondii infection not affect the odds of 
developing non-affective psychosis, whereas among neonates with low APP levels there was 
a pattern of increased odds (Figure 4). When restricting the analyses to cases of schizophrenia 
only, neonates with low APP levels and maternal reactivity against T. gondii had substantially 
increased odds of developing schizophrenia. Indeed, a low APP-score and maternal exposure 
to T. gondii significantly increased the odds of developing non-affective psychosis OR 2.1, 
95% CI: 1.1, 4.0 and schizophrenia, OR 3.6, 95% CI: 1.0, 13.4. Only low neonatal levels of 
fibrinogen in combination with maternal reactivity towards T. gondii reached significant 
interaction, RERI 1.1, 95% CI: 0.0, 2.2. 
Maternal exposure to CMV did not increase the odds of developing non-affective psychosis 
among neonates with high APP levels (Figure 5). Neonates with low levels of SAP, 
procalcitonin or tPA and maternal reactivity against CMV had increased odds of developing 
non-affective psychosis. Restricting the analyses to schizophrenia only, maternal exposure to 
CMV increased the odds of developing schizophrenia even among those with high levels of 
APPs, or with a high APP score (Figure 5). Maternal reactivity against CMV and low APP 
levels (except ferritin) or with a low APP-score was significantly associated with increased 
odds of schizophrenia development. Once more, being in the lower tertile of fibrinogen 
together with maternal reactivity towards CMV the OR for schizophrenia increased by 6-fold 
as compared to those unexposed to CMV, or with high APPs. The odds of developing 
schizophrenia increased to significantly levels among neonates with maternal CMV exposure 
and a low APP score, OR 6.0, 95% CI: 1.1, 33.1. 
 
 
 
 
 
 
 
 34 
 A
P
P
  
T
. 
g
o
n
d
ii
 
C
o
n
tr
o
ls
 
  
N
e
o
n
a
te
s
 w
h
o
 w
ill
 d
e
v
e
lo
p
 n
o
n
-a
ff
e
c
ti
v
e
  
p
s
y
c
h
o
s
is
, 
IC
D
-1
0
 F
2
0
-2
9
 
  
N
e
o
n
a
te
s
 w
h
o
 w
ill
 d
e
v
e
lo
p
 s
c
h
iz
o
p
h
re
n
ia
, 
 
IC
D
-1
0
 F
2
0
 
U
n
e
x
p
o
s
e
d
 
(n
=
4
0
3
) 
 
E
x
p
o
s
e
d
 
 (
n
=
1
2
2
) 
p
 
U
n
e
x
p
o
s
e
d
 
(n
=
1
5
3
) 
 
E
x
p
o
s
e
d
 
 (
n
=
4
6
) 
p
 
U
n
e
x
p
o
s
e
d
 
(n
=
3
0
) 
E
x
p
o
s
e
d
 
(n
=
1
6
) 
p
 
a
-2
-M
a
c
ro
g
lo
b
u
lin
 (
n
g
/m
l)
 
3
5
7
 (
1
3
7
-6
1
5
) 
 
5
9
4
 (
3
5
2
-8
9
5
) 
**
* 
3
4
0
 (
1
5
8
-5
8
9
) 
4
2
0
 (
1
2
9
-8
2
4
) 
n
s
 
2
8
2
 (
1
0
1
-5
0
8
 
3
6
8
 (
1
2
8
-6
0
6
) 
n
s
 
H
a
p
to
g
lo
b
u
lin
 (
n
g
/m
l)
 
6
.0
 (
2
.6
-2
1
.1
) 
 
1
1
.2
 (
3
.3
-3
6
.4
) 
**
* 
6
.3
 (
2
.5
-1
5
.7
) 
6
.4
 (
2
.3
-2
2
.4
) 
n
s
 
6
.2
 (
2
.1
-4
2
.1
) 
6
.6
 (
1
.6
-2
3
.9
) 
n
s
 
C
-r
e
a
c
ti
v
e
 p
ro
te
in
 (
n
g
/m
l)
 
0
.6
 (
0
.2
-1
.8
) 
1
.1
 (
0
.5
-2
.4
) 
**
 
0
.6
 (
0
.2
-1
.3
) 
0
.8
 (
0
.2
-2
.2
) 
n
s
 
0
.5
 (
0
.1
-1
.3
) 
0
.3
 (
0
.1
-1
.2
) 
n
s
 
S
e
ru
m
 a
m
y
lo
id
 P
 (
n
g
/m
l)
 
1
0
.3
 (
5
.1
-1
6
.1
) 
1
3
.8
 (
7
.8
-2
0
.5
) 
**
* 
8
.8
 (
4
.7
-1
5
.2
) 
1
1
.0
 (
6
.1
-1
6
.0
) 
n
s
 
8
.6
 (
4
.2
-1
3
.3
) 
1
0
.0
 (
5
.1
-1
2
.5
) 
n
s
 
P
ro
c
a
lc
it
o
n
in
 (
p
g
/m
l)
 
2
.1
 (
0
.8
-3
.3
) 
3
.3
 (
1
.4
-5
.2
) 
**
* 
1
.9
 (
0
.8
-3
.2
) 
2
.6
 (
0
.8
-4
.4
) 
n
s
 
2
.0
 (
0
.3
-2
.6
) 
2
.2
 (
0
.2
-4
.4
) 
n
s
 
F
e
rr
it
in
 (
p
g
/m
l)
 
1
1
3
0
 (
3
0
1
-2
5
0
0
) 
2
3
5
0
 (
6
6
5
-4
7
6
0
) 
**
* 
1
4
3
0
 (
3
3
1
-2
8
3
0
) 
1
8
0
0
 (
2
6
0
-4
2
9
0
) 
n
s
 
1
0
8
0
 (
2
2
0
-2
5
8
0
) 
1
2
5
0
 (
1
5
0
-3
9
2
0
) 
n
s
 
tP
A
 (
p
g
/m
l)
 
3
.6
 (
1
.3
-6
.0
) 
4
.8
 (
2
.2
-6
.9
) 
* 
3
.1
 (
1
.0
-5
.3
) 
2
.2
 (
0
.0
-5
.6
) 
n
s
 
2
.9
 (
0
.8
-4
.9
) 
2
.3
 (
0
.0
-4
.4
) 
n
s
 
F
ib
ri
n
o
g
e
n
 (
n
g
/m
l)
 
6
.8
 (
2
.2
-1
7
.9
) 
1
4
.9
 (
2
.7
-4
6
.2
) 
**
 
7
.6
 (
2
.6
-2
4
.9
) 
3
.6
 (
1
.2
-2
0
.9
) 
n
s
 
3
.7
 (
2
.7
-2
6
.5
) 
2
.6
 (
0
.4
-1
3
.0
) 
n
s
 
S
e
ru
m
 a
m
y
lo
id
 A
 (
n
g
/m
l)
 
1
.6
 (
0
.7
-3
.5
) 
2
.2
 (
1
.0
-5
.0
) 
**
 
1
.5
 (
0
.7
-2
.9
) 
1
.2
 (
0
.4
-2
.4
) 
n
s
 
1
.7
 (
0
.7
-2
.1
) 
1
.2
 (
0
.0
-2
.3
) 
n
s
 
A
P
P
 s
c
o
re
 
0
.1
 (
-0
.7
-0
.6
) 
0
.6
 (
-0
.8
-1
.1
) 
**
* 
0
.2
 (
-0
.6
-0
.5
) 
0
.1
 (
-0
.6
-0
.8
) 
n
s
 
0
.1
 (
-0
.8
-0
.5
) 
-0
.2
 (
-1
.1
-0
.4
) 
n
s
 
 
 
 
 
A
P
P
  
C
M
V
 
C
o
n
tr
o
ls
 
  
N
e
o
n
a
te
s
 w
h
o
 w
ill
 d
e
v
e
lo
p
 n
o
n
-a
ff
e
c
ti
v
e
  
p
s
y
c
h
o
s
is
, 
IC
D
-1
0
 F
2
0
-2
9
 
  
N
e
o
n
a
te
s
 w
h
o
 w
ill
 d
e
v
e
lo
p
 s
c
h
iz
o
p
h
re
n
ia
, 
 
IC
D
-1
0
 F
2
0
 
U
n
e
x
p
o
s
e
d
 
(n
=
1
3
5
) 
E
x
p
o
s
e
d
 
(n
=
3
9
0
) 
p
 
U
n
e
x
p
o
s
e
d
 
(n
=
4
8
) 
E
x
p
o
s
e
d
 
(n
=
1
5
1
) 
p
 
U
n
e
x
p
o
s
e
d
 
(n
=
8
) 
E
x
p
o
s
e
d
 
(n
=
3
8
) 
p
 
a
-2
-M
a
c
ro
g
lo
b
u
lin
 (
n
g
/m
l)
 
3
4
8
 (
8
3
.2
-5
8
8
) 
4
3
1
 (
1
8
7
-6
9
8
) 
**
 
3
4
0
 (
1
0
0
-5
6
5
) 
3
5
5
 (
1
5
9
-6
7
8
) 
n
s
 
3
4
3
 (
1
2
8
-5
2
1
) 
3
3
6
 (
1
0
1
-5
5
1
) 
n
s
 
H
a
p
to
g
lo
b
u
lin
 (
n
g
/m
l)
 
5
.1
 (
2
.3
-1
7
.5
) 
7
.2
 (
2
.8
-2
7
.8
) 
* 
5
.7
 (
2
.2
-2
2
.3
) 
6
.5
 (
2
.8
-1
6
.1
) 
n
s
 
1
.9
 (
1
.6
-3
7
.5
) 
7
.1
 (
2
.4
-3
7
.0
) 
n
s
 
C
-r
e
a
c
ti
v
e
 p
ro
te
in
 (
n
g
/m
l)
 
0
.7
 (
0
.2
-2
.0
) 
0
.8
 (
0
.2
-1
.9
) 
n
s
 
0
.8
 (
0
.2
-1
.7
) 
0
.6
 (
0
.2
-1
.4
) 
n
s
 
0
.8
 (
0
.1
-0
.9
) 
0
.4
 (
0
.1
-1
.2
) 
n
s
 
S
e
ru
m
 a
m
y
lo
id
 P
 (
n
g
/m
l)
 
9
.4
 (
4
.3
-1
6
.5
) 
1
1
.5
 (
6
.1
-1
8
.0
) 
* 
8
.9
 (
5
.8
-1
4
.3
) 
8
.9
 (
4
.8
-1
7
.0
) 
n
s
 
7
.9
 (
6
.0
-1
0
.8
) 
9
.0
 (
4
.2
-1
3
.3
) 
n
s
 
P
ro
c
a
lc
it
o
n
in
 (
p
g
/m
l)
 
1
.9
 (
4
.3
-1
6
.5
) 
2
.3
 (
0
.9
-3
.8
) 
* 
1
.8
 (
0
.8
-3
.2
) 
2
.0
 (
0
.8
-3
.5
) 
n
s
 
2
.3
 (
0
.4
-3
.5
) 
1
.9
 (
0
.3
-3
.5
) 
n
s
 
F
e
rr
it
in
 (
p
g
/m
l)
 
9
6
5
 (
1
9
1
-2
4
1
0
) 
1
5
9
0
 (
4
3
9
-3
1
8
0
) 
**
 
1
2
3
0
 (
2
5
9
-2
7
2
0
) 
1
7
3
0
 (
3
3
5
-3
1
3
0
) 
n
s
 
9
6
0
 (
2
5
0
-2
0
8
0
) 
1
1
8
0
 (
1
2
0
-2
6
6
0
) 
n
s
 
tP
A
 (
p
g
/m
l)
 
3
.0
 (
0
.9
-5
.8
) 
4
.1
 (
2
.0
-6
.4
) 
* 
2
.8
 (
1
.0
-4
.8
) 
3
.1
 (
0
.5
-5
.6
) 
n
s
 
2
.4
 (
0
.6
-5
.3
) 
2
.9
 (
0
.2
-4
.6
) 
n
s
 
F
ib
ri
n
o
g
e
n
 (
n
g
/m
l)
 
5
.2
 (
2
.0
-1
7
.0
) 
8
.2
 (
2
.4
-2
7
.3
) 
* 
5
.3
 (
2
.5
-1
6
.0
) 
7
.4
 (
2
.1
-2
6
.2
) 
n
s
 
3
.5
 (
3
.0
-2
0
.0
) 
3
.4
 (
1
.4
-2
6
.1
) 
n
s
 
S
e
ru
m
 a
m
y
lo
id
 A
 (
n
g
/m
l)
 
1
.4
 (
0
.6
-3
.0
) 
1
.8
 (
0
.9
-4
.1
) 
* 
1
.2
 (
0
.5
-3
.0
) 
1
.6
 (
0
.6
-2
.8
) 
n
s
 
0
.9
 (
0
.2
-2
.4
) 
1
.5
 (
0
.6
-2
.1
) 
n
s
 
A
P
P
 s
c
o
re
 
0
.1
 (
-1
.1
-0
.6
) 
0
.3
 (
-0
.5
-0
.8
) 
* 
0
.1
 (
-0
.5
-0
.6
) 
0
.1
 (
-0
.6
-0
.6
) 
n
s
 
-0
.3
 (
-0
.6
-0
.5
) 
0
.1
 (
-1
.0
-0
.4
) 
n
s
 
* 
=
 p
≤
0
.0
5
, 
**
 =
 p
≤
0
.0
1
, 
**
* 
=
 p
≤
0
.0
0
1
, 
n
s
=
n
o
n
 s
ig
n
if
ic
a
n
t 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
a
b
le
 4
. 
M
a
n
n
-W
h
it
n
ey
 U
-t
es
t,
 p
-v
a
lu
es
 o
f 
th
e 
d
if
fe
re
n
ce
 i
n
 l
ev
el
s 
o
f 
a
cu
te
 p
h
a
se
 p
ro
te
in
s 
a
m
o
n
g
 n
eo
n
a
te
s 
to
 e
x
p
o
se
d
 a
n
d
 u
n
ex
p
o
se
d
 m
o
th
er
s 
(m
ed
ia
n
, 
2
5
th
-
7
5
th
 p
er
ce
n
ti
le
),
 c
o
n
tr
o
ls
 a
n
d
 c
a
se
s 
se
p
a
ra
te
ly
. 
(S
tu
d
y
 I
I)
 
*
=
p
<
0
.0
5
, 
*
*
=
p
<
0
.0
1
, 
*
*
*
=
p
<
0
.0
0
1
, 
n
s=
n
o
n
-s
ig
n
if
ic
an
t 
  35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Odds ratios (OR) and 95% confidence intervals of Non-affective psychosis or Schizophrenia 
according to maternal T. gondii exposure status and levels of each APP (lowest 1/3 tertile, and highest 2/3 
tertile) and APP-score (below median and above median). (Study II) 
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Figure 5. Odds ratios (OR) and 95% confidence intervals of Non-affective psychosis or Schizophrenia 
according to maternal CMV exposure status and levels of each APP (lowest 1/3 tertile, and highest 2/3 
tertile) and APP-score (below median and above median). (Study II) 
 
5.3 STUDY III 
Of totally 1 172 879 children followed up in the registers, 4 638 (0.4%) were subsequently 
diagnosed with non-affective psychoses. There was a modest but significant association 
between any severe infection during childhood and non-affective psychoses, HR 1.10, 95% 
CI: 1.03, 1.18 (Table S3). The risk did not differ by age at time of infection. 
The association was strongest between hospital admission with bacterial infection and the 
later development of non-affective psychoses, HR 1.23, 95% CI: 1.08, 1.40, where exposure 
  37 
to bacterial infection during preadolescence (10-13 years) was associated with the highest 
risk estimate, HR 1.59, 95% CI: 1.22, 2.08 (Figure 6). 
 
 
Figure 6. Hazard Ratio (HR) (95% CI) of schizophrenia after hospital admission with infection during 
childhood 0-13 years. (Study III) 
CNS infection was not associated during any age period, with one exception, during 
preadolescence, HR 1.96, 95% CI: 1.06, 3.65.  
Four or more admissions with infection during childhood had slightly stronger risk estimates 
than one admission, HR 1.37, 95% CI: 1.06, 1.78. 
In study III, adjusting for psychiatric disorder in general among parents had stronger effects 
on the estimate than adjusting only for the more restricted diagnoses of schizophrenia or non-
affective psychosis (Table 5). 
 
 
  
                                                                                                                                                      
Table 5. Effect of parental psychiatric diagnoses on the association between 
childhood infection and non-affective psychosis among offspring. (Study III) 
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5.4 STUDY IV 
Of totally 1 971 623 children, 8 330 (0,4%) were subsequently diagnosed with non-affective 
psychoses during follow-up. There was no association between maternal hospitalization for 
infection during pregnancy and non-affective psychosis among offspring in the fully adjusted 
model, OR 1.06, 95% CI: 0.88, 1.27. Type of infection (bacteria or virus) or trimester at time 
of infection did not modify the association (Table S4). In contrast, among individuals whose 
parents were diagnosed with a psychiatric disorder, exposure to maternal infection during 
pregnancy was significantly associated with non-affective psychosis, HR 1.30, 95% CI: 1.02, 
1.66. Among individuals without parental psychiatric disorder there was no association, HR 
0.84, 95% CI: 0.63, 1.11. 
Further exploring a familial liability for infection; maternal infection up to 5 years prior to 
pregnancy was modestly associated with non-affective psychosis in the offspring, (HR 1.14, 
95% CI: 1.05, 1.23). Paternal hospital admission with infection prior to pregnancy was not, 
(HR 0.97, 95% CI: 0.86, 1.09) 
There was indication of interaction between maternal psychiatric disorder and infection 
during pregnancy in the development of non-affective psychosis among offspring, RERI 
0.79, 95% CI -0.02, 1.60, especially among mothers who were not hospitalized with infection 
prior to pregnancy, RERI 1.33. 95% CI: 0.27, 2.39 whereas paternal psychiatric disorder did 
not affect the associations, RERI 0.14, 95% CI: -0.59, 0.87(Figure 7). 
Maternal infection during pregnancy per se or a familial liability for infections (i.e. maternal 
infection prior to pregnancy) was investigated on the odds of being hospitalized with 
infection during childhood (Table 6). There was an association both between maternal 
infection during pregnancy as well as maternal infection prior to pregnancy in the general 
population. Among individuals who later developed non-affective psychosis maternal 
infection particularly during pregnancy further increased the odds of childhood admission 
with infection, OR 2.12, 95% CI: 1.46, 3.07. 
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There was interaction between maternal infection during pregnancy and childhood infection 
in the risk of developing non-affective psychosis RERI 0.45, 95% CI 0.03, 0.87, whereas no 
interaction was found between maternal infection prior to pregnancy and admission with 
infection during childhood on the risk of developing non-affective psychosis RERI -0.07, 
95% CI: -0.25, 0.11 (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. HR and 95% CI of non-affective psychoses according to maternal infection during pregnancy 
respectively up to 5 years before pregnancy, and childhood infection. Fully adjusted for birth year, sex, 
urban birth, winter birth, parental age ≥ 35 years, small for gestational age, parental history of 
psychiatric disorder, parent born outside Sweden, low SES, any parent any inpatient care before or 
during pregnancy except for treatment of infection or psychiatric care, and for the child during childhood 
(0-13 y) . Circles represent the general population and diamonds the restricted model. (Study IV)  
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6 DISCUSSION 
6.1 MAIN FINDINGS IN THE CONTEXT OF PREVIOUS STUDIES 
6.1.1 Maternal infection during pregnancy 
6.1.1.1 Chronic maternal infections 
In Study I, we found support for an association between maternal exposure to T. gondii and 
schizophrenia in offspring. This is the third study to find such an association 
61,63
. In these 
studies, including ours, a dose-response relationship was observed, which strengthens the 
probability of a true association. Increased antibody levels could imply a more recent 
maternal exposure and perhaps increased pathogen or immune component levels during the 
pregnancy, which could have greater impact on the fetus. Although we aimed to have a larger 
sample size than previous studies, we had a large drop-out and ended up with a study 
population similar to the previous ones. Thus, all studies, including the two studies that did 
not find support for an association 
56,58
 have had low power to detect a true difference 
between exposed and unexposed mothers.  
Apart from MIA and a potential transmission of the pathogen, the observed associations 
between elevated maternal IgG antibodies and psychotic disorder could be interpreted as 
markers of a high load of the pathogen in the environment/family. For example, high levels of 
maternal T. gondii IgG could be a marker of cat ownership 
159
, which may imply an increased 
probability of later exposure, with a more causal association. Indeed, individuals with 
schizophrenia have increased levels of antibodies directed at T. gondii 
160
. This theory could 
also be true also for infections in general, e.g., bad hygiene habits in the family may imply 
increased susceptibility of infections overall. 
This is the first study to find an association between chronic maternal CMV infection and 
schizophrenia in offspring. Unfortunately, the previous two studies that did not find support 
for an association had low power to detect a difference, as was also the case in our study, 
56,62
. 
In addition, as the worldwide prevalence is high but varies considerably between decades, 
countries and in different age groups, it is important to consider the prevalence in the study 
population when determining the cut-off level for negative and positive exposure status. It is 
possible that the two negative studies misclassified the exposure (comparing exposed 
individuals with a mix of unexposed and exposed individuals), thus underestimated the 
association.   
The biological mechanisms behind the schizophrenia risk associated with chronic maternal 
CMV infection during pregnancy are unknown. We have for example no knowledge whether 
the pathogen is transmitted to the fetus. Recently, an increased prevalence of CMV DNA was 
found in neonatal blood from children diagnosed with autism. Interestingly, these children 
had no signs of congenital CMV infection 
161
. There are reports of a link between genetic 
variability in the MHC-region as well as in the TNF-region, CMV infection and 
schizophrenia risk 
148,162,163
, which suggest the involvement of immunological mechanisms.  
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Several studies indicate an altered immune response among patients with schizophrenia 
118,132,164
. Such deficiencies seem to be already present at birth. Gardner et al. recently 
reported that neonates who will develop non-affective psychosis have low levels of some 
APPs 
117
.  
In Study II, we investigated whether maternal infection during pregnancy affected neonatal 
levels of APP. We found that those in the control group who had mothers with chronic 
T.gondii and CMV infection had elevated APP levels. In contrast, neonates who later 
developed non-affective psychosis did not have elevated APP levels. Interestingly, cases and 
controls with unexposed mothers had the same low levels of APP. Thus, the low levels 
among cases indicate a deficient response to maternal infections rather than low circulating 
levels. In addition, we found evidence of T.gondii increasing the risk of non-affective 
psychosis only among neonates who did not have elevated APP levels. Hence, individuals 
who later develop psychotic disorder seem to respond inadequately to some chronic maternal 
infections which increase the vulnerability to these exposures. These findings support the 
hypothesis of a deficient innate immune response in the aetiology of schizophrenia 
131
. 
However, these findings should be interpreted with caution, though our studies had several 
methodological weaknesses, which are described in the Methodological considerations 
section.  
Including Study I, three studies have found and three have not found support for an 
association with HSV-2. Apart from methodological limitations in all studies, these 
discrepancies could be explained by variation in circulating HSV-2 genotypes on different 
continents and during various decades 
165
. 
We found no evidence of an association between chronic maternal HSV-1 infection and 
schizophrenia which is in accordance with all previous studies 
56,62,63
. Although the reliability 
of these studies is limited, it nevertheless appears that chronic maternal HSV-1 infection 
during pregnancy is not a risk factor for non-affective psychosis.    
6.1.1.2 Maternal hospital admission with infection 
In Study IV, we did not find support for an association between maternal infection during 
pregnancy and non-affective psychosis in offspring overall. Nor did we find evidence of 
infections restricted to only bacteria respectively only virus to increase the risk of psychosis. 
The two previous studies that reported positive associations with respiratory respectively 
bacterial infections had few exposed cases 
99,102
. The study investigating any infections 
during pregnancy in a large population based birth cohort found a modest association, 
RR=1.2 
103
. Notably, neither of these studies were adjusted for important confounders such as 
parental migration, SES, psychiatric history in the family and care-seeking habits which 
could explain the differing results. In fact a psychiatric (not only psychotic) history and care-
seeking habits in the family (parental admission to hospital before and during pregnancy) had 
the largest attenuating effects on our estimates. Our crude estimates were similar to those in 
the latter study.  
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To distinguish the specific effect of infection in utero from the genetic overlap of liability for 
both infection and schizophrenia, we compared the risks associated with maternal and 
paternal infection before and during pregnancy. Only one previous study has investigated the 
association between both maternal and paternal infection and offspring schizophrenia 
103
.  
We found a modest familial susceptibility to severe infection; maternal infection prior to 
pregnancy was weakly associated with offspring psychosis. However, the fact that no 
evidence of an association was found for paternal infection before pregnancy speaks against a 
general familial susceptibility to infections among patients with non-affective psychoses, as 
was reported for patients with schizophrenia by Nielsen et al. 
103
. That study, however, 
included parental infections after the birth of the index child where infection transmission 
within the family may have occurred 
104,105
, whereby an effect specific to the foetal period 
could not be ruled out.  
We found a synergistic effect between maternal psychiatric disorder and maternal infection 
during pregnancy, but not before pregnancy in the risk of non-affective psychosis in 
offspring. These findings imply a specific intrauterine effect of maternal infection per se 
among vulnerable mothers. The evidence of interaction is discussed further in the Two-hits 
section below.  
6.1.2 Childhood infection 
In Study III, we found a moderate association between hospital admission with any infection 
during childhood (0-13 years of age) and non-affective psychosis later in life. Bacterial 
infection and infection in the CNS, especially during the pre-adolescence period, had the 
strongest association after adjusting for infections during previous age periods. The same 
infection diagnoses were used in a Danish population based study, published concurrently 
with our study 
166
. The Danish study found slightly stronger associations between any 
infections at 10-14 years of age and schizophrenia. However, they had not adjusted for care-
seeking habits which had an attenuating effect on our estimates. Interestingly, similar to our 
results, the strongest associations were with bacterial infections.  
The mechanisms behind these findings are not known. However, the associations observed 
with bacterial infection could mirror the effects of treatment with antibiotics. As mentioned 
previously, a dysfunctional microbiom in the gut may be involved in the aetiology of 
neuropsychiatric disorders 
144
. Regarding the associations specifically during the pre-
adolescence period sparse support can be found in the literature: During the pre-adolescence 
period, the normal pruning processes of the brain imply reduction in plasticity and decrease in 
synaptic contacts. This process is suggested to be exaggerated and lead to the prodromal 
symptoms seen in schizophrenia patients 
45,167
. Additionally, it is recognized that some 
infections are more prevalent during adolescence, indicating that this period is sensitive for 
infection 
168
. Thus, studies assessing infection during these years in relation to prodromal 
symptoms are of importance.  
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6.1.3 Multiple hits? 
In Study IV, we found support for the two-hit theory of schizophrenia, as in our data infection 
during foetal life was only associated with psychosis development in conjunction with 
genetic vulnerability. Genetic vulnerability per se was strongly associated with non-affective 
psychosis development, but the association became even stronger in combination with 
infection during foetal life. Similarly, Clarke et al. reported on synergism between parental 
history of psychotic disorder and maternal pyelonephritis during pregnancy in the risk of 
schizophrenia in offspring 
101
. Parental psychiatric disorder is a crude marker of genetic 
vulnerability. Although there is genetic overlap between many neuropsychiatric disorders, 
and they share many environmental risk factors 
169
, relatively few patients with schizophrenia 
have parents with psychiatric disorder 
6
. Moreover, mothers with psychiatric disorder may 
have a different intrauterine environment in terms of medication, BMI, or life-style, which 
could explain the observed interaction. We adjusted for care-seeking habits, SES and parental 
migration, which should take care of some of the confounding effect, but there is a risk of 
residual confounding. Interestingly, specifically maternal but not paternal genetic load was 
part of the association. 
Consistent with a “two-hit” model is that prenatal environmental factors or stressors could 
have priming effects or sensitize the brain or the immune system, increasing the vulnerability 
and the susceptibility to later insults 
119,170
. In Study IV, we found that foetal and childhood 
infection acted synergistically in the development of non-affective psychosis. This suggests 
that among individuals who will develop non-affective psychosis later in life, prenatal 
infection affects the child for a greater insult by a second stressor in terms of childhood 
infection. An interesting question is whether a carrier of genes susceptible to psychotic 
disorder (e.g., in the MHC-region) who is exposed to severe infections on multiple occasions 
is at higher risk of developing the disease than a carrier who has been protected against 
serious infections, suggestive of not only a “two-hit” but a “multiple-hit” model. 
Unfortunately, we had too few cases in the strata to investigate genetic vulnerability in terms 
of parental psychiatric disorder in conjunction with both foetal and childhood infection.  
6.1.4 The pathophysiology of psychosis in context of infection during foetal 
life and childhood  
The pathoaetiology of schizophrenia is unknown but the hyperdopamine and hypoglutamate 
hypotheses are the most recognized 
171,172
. In the 1950s Carlsson et al., discovered DA in the 
brain, which led to the dopamine hypothesis in schizophrenia 
171,172
. This hypothesis gained 
clinical support due to observations of drugs that stimulate the DA-system (e.g., 
amphetamine), inducing psychotic symptoms in healthy individuals, as well as observations 
that antipsychotic drugs that reduce the positive symptoms present in schizophrenia block the 
DA D2-receptors 
173,174
. However, the modest reduction in negative symptoms induced by 
antipsychotic drugs eventually led to the dopamine-imbalance theory of schizophrenia 
involving impaired DA D1-receptor signaling 
175,176
. Later, Phencyclidine (PSP) and the 
anaesthetic drug Ketamine were observed to cause both positive and negative symptoms as 
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well as cognitive impairments similar to those seen in schizophrenia 
177
. Subsequently, the 
NMDA receptor hypofunction hypothesis was proven when PCP and Ketamine were found  
to inhibit the glutamate NMDA-receptor 
178
. More recently, it has become increasingly 
evident that the altered neurotransmission in schizophrenia involves an intricate balance 
between inhibition, and activation as well as interactions between not only dopamine and 
glutamate but also other neurotransmitters such as GABA, and acetylcholine and their 
receptors in complex neural circuits, reviewed in 
179
.  
6.1.4.1 Kynurenic acid 
Kynurenic acid (KYNA) is potentially an underlying pathophysiological mechanism of 
schizophrenia development that has been extensively investigated 
180
. The amino acid 
Tryptophan, an essential brick in protein synthesis, is degraded through the kynurenine 
pathway and KYNA is one of the end products. KYNA has similar characteristics to PCP and 
Ketamine in that it blocks the NMDA-receptor 
181
. Of relevance for schizophrenia 
development is the fact that experimental studies have revealed that elevated KYNA 
increases DA-activity 
182
. Moreover, elevated levels of KYNA have been found in the 
cerebrospinal fluid (CSF) and prefrontal cortex in small samples of schizophrenia patients 
183-
185
. Interestingly, many infections are associated with the degradation of Tryptophan through 
the kynurenine pathway, and elevated levels of KYNA have been measured in cerebrospinal 
fluid (CSF) in conjunction with infection 
186,187
. Speculatively, KYNA could thus be a link 
between infection and psychotic disorder.  
6.1.4.2 Vagus nerve 
The brain is regulated from the periphery by means of both humoral and neural pathways. 
Cytokines are involved in the humoral dialogue between the peripheral immune system and 
the CNS, where the vagus nerve is the neural actor in the cross-talk between the two 
188
. The 
vagus nerve is part of a neural circuit called the cholinergic anti-inflammatory pathway 
(CAP) in which nerve signals from the periphery to the brain and back again regulate 
inflammation at the periphery 
189
. Cytokine receptors on the efferent arc of the vagus  nerve 
become activated on infection/inflammation and transfer signals along the axon of the nerve 
via the brain stem to central parts of the brain 
188
. What happens when the signal reaches the 
central parts of the brain is not completely understood, but neuroimaging studies report 
change in blood flow and activity in many of the brain regions implicated in neuropsychiatric 
disorders 
190
. It can be speculated whether the vagus nerve is a link between infection and 
brain alterations. 
6.1.5 Additional findings 
One finding that may be of interest outside the research area of this thesis is that chronic 
maternal T. gondii and CMV infection seem to affect the innate immune response in the 
neonate. So far only chronic maternal parasite and helminthe infections common in 
developing countries have been reported to affect the child’s immune response 119. These 
alterations are independent of pathogen transmission and are present for several years.  
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6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Study design 
6.2.1.1 Case-control studies 
In a case-control study affected individuals (cases) are selected from a source population, 
after which a number of unaffected individuals (controls) are randomly selected from the 
same population to serve as a comparison group. A case-control study is effective when there 
are few resources, such as biological samples available (Study I and II). The disadvantage is 
that case-control studies are very sensitive to selection bias and may be inefficient for rare 
exposures. It is not possible to estimate risks or rates from a case-control study as only a 
sample is selected from the population. Instead, an odds ratio (OR) can be estimated, defined 
as the odds of being a case if exposed, compared to the odds of being a case if not exposed. 
However, the OR can be interpreted as a relative risk if the outcome condition is rare 
157
.     
6.2.1.2 Cohort studies 
In a cohort study a group of people who share similar characteristics, e.g., born during a 
particular time period and in a specific geographic area, are followed up until a fixed end 
point, e.g., death or a given date. A cohort study can either be prospective or retrospective. If 
prospective, data about the study population are collected before the start of follow-up, which 
minimizes measurement errors and increases the possibility to select as many potential 
confounders as possible. A prospective cohort study is not suitable for investigating rare 
conditions or those that takes time to develop or are rare though it tends to become very 
expensive and time consuming.  In a retrospective cohort study, data are collected after 
having been recorded in, for example, a register, making it time efficient and more 
convenient. The disadvantage is that the study is restricted to pre-existing data of exposure, 
outcome and confounding factors. However, the Swedish registers used in this thesis (Study 
III and IV) include just about the total population and collectively information on many 
factors.  
6.2.2 Random errors 
The precision of a study reflects the certainty of an estimate not being affected by random 
errors. Random errors are due to chance and related to the variability in the data. The larger 
the sample size the less is the likelihood of random errors. The CI reflects the degree of 
certainty (e.g., 95%) that the point estimate will lie within the interval if the study was 
replicated repeatedly. The same formula is used to estimate both the p-value and the CI. 
Hence, a p-value <0.05 is analogous to a 95% CI that does not including the null value. Study 
I and II are fairly small studies and the likelihood of random errors is therefore large, with 
wide confidence intervals.  
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6.2.3 Systematic errors 
6.2.3.1 Selection bias 
Selection bias is caused by how the participants are recruited to the study and occurs when 
the association between exposure and outcome differ between those included in the study and 
those who are not (the remaining source population). The risk of selection bias is particularly 
high in case-control studies. 
In study I and II, cases were retrieved from both in- and outpatient registers. However, those 
treated in primary care only are not included. There is therefore a limited risk of selection of 
more serious cases. 
In study I and II an inclusion criterion for the controls was no in-patient treatment for a 
psychiatric diagnosis, which made them “healthier” than the source population and may have 
introduced selection bias. The controls were no longer representative of the source population 
from which the cases were selected. As a psychiatric disorder may be associated with the 
exposure, the exposure tendency among the controls might have been lower than in the 
source population and the association overestimated. However, it is possible that the controls 
had been treated in primary care or psychiatric outpatient clinics. About 25% of individuals 
with non-affective psychosis are only found in out-patient care registers in Stockholm County 
Council 
28
. Moreover, less acute psychiatric disorders such as depression are mainly treated in 
outpatient care 
1
.   
A large drop-out among both cases and controls occurred in study I and II and could have led 
to selection bias had it occurred in a systematic manner. However, there was no selection of 
less serious cases, as the proportion of schizophrenia of those who agreed and those who 
declined to participate was the same. In the final sample the proportion of immigrants was the 
same in the control group and the source population. In addition, cases and controls who 
declined to participate had the same distribution of birth year and sex as the cases and 
controls included in the study, thus there was no indication of selection bias. 
The risk of selection bias in total population cohort studies (Study III and IV) is limited.  
6.2.3.2 Information bias 
Information bias occurs due to misclassification or measurement errors. When the 
misclassification is equal among the two study groups (cases and controls, or exposed and 
unexposed) it is termed non-differential (random) misclassification. This type of 
misclassification is common in observational studies and weakens the association. If the 
misclassification differs between the two groups it may bias the estimate in both directions. In 
this thesis the main sources of misclassification are the ascertainment of exposure to infection 
in the biological samples, the criterion of only hospital treated infections and the validity of 
the diagnoses in the registers.  
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Misclassification of the exposure 
In study I and II, there is a risk of exposure misclassification as there are no predefined 
antibody levels corresponding to positive exposure. Instead, age-weighted seroprevalences of 
the different pathogens among pregnant women during the period 1975-85 were used to find 
the positive and negative exposure status limit in terms of antibody levels. We have no reason 
to believe that these misclassifications differed between cases and controls, whereby the 
results should not have been affected to any great extent.  
Laboratory analyses always involve a risk of faulty instruments or human error. In study I 
and II all laboratory analyses were blinded to case control status. Thus, there is no reason to 
believe that these potential errors are differential. 
In study III and IV diagnoses of infection were collected from the NPR. Validation studies 
that compared the diagnoses recorded in the NPR and medical records have shown a positive 
predictive value of about 80% for somatic diagnoses 
191
. 
In study III and IV we only had information on infections that required hospital treatment. A 
number of factors associated with psychotic disorder, such as social inabilities, and a small 
social network, may increase the probability of being hospitalized with infection given the 
same degree of severity of infection as compared to families without such problems. This 
would imply a higher probability of cases being detected in hospital registers. Circumstances 
such as social inability could also imply less care-seeking tendencies in the family. 
Consequently, there were risks of differential misclassification, which could have affected the 
estimates in either direction, in study III and IV.   
Misclassification of the outcome 
The diagnoses of non-affective psychosis were based on register data rather than individual 
assessment. In study I and II the diagnoses of non-affective psychoses were collected from 
both the NPR and the PVS. The PVS has been validated by comparing registered diagnoses 
of non-affective psychoses with medical records 
20
.  
In study III and IV, diagnoses of non-affective psychosis were collected from the NPR. 
Validation studies that compared the diagnoses recorded in the NPR and medical records 
have shown a positive predictive value of 85-95% for psychiatric diagnoses 
191-193
. In study 
III, only cases with inpatient care were included. From 1995, the Swedish Mental Health 
Care reform led to a shift from institutionalized psychiatric care to treatment in outpatient 
care. Thus, there is a risk of underestimation of the cases in study III. In study IV, both 
inpatient and outpatient care were included. However, the outpatient register did not have 
complete coverage until 2005, whereby there is a risk that all incident cases were not 
captured 
28
. The underestimation of the cases in study III and IV probably led to dilution of 
the estimates. 
 50 
6.2.3.3 Confounding 
Confounding is a common systematic error in observational studies and threatens the validity 
by interfering with the effect of the exposure on the outcome. By definition a confounder has 
to be associated with both the exposure and the outcome, but cannot be present on the causal 
pathway between them (i.e., cannot be an effect of the exposure). There are several ways of 
dealing with confounding in the study design, e.g., randomization, restriction, and matching 
as well as in the analysis, e.g., matching, stratification, and regression modelling. All studies 
in this thesis used regression modeling to adjust for multiple confounding variables. 
Confounding factors considered were based on à priori knowledge of potential risk factors to 
the outcome and associated with the exposure.  
Study I and II          The controls were matched to the cases in terms of sex (infection and 
non-affective psychosis more common among males), birth date (time dependent birth excess 
in relation to exposure status and outcome), and birth hospital (differing hospital routines 
may affect both exposure and outcome) to minimize confounding by these factors. In 
addition, maternal age ≥35 years was considered a confounder, as older mothers tend to have 
higher levels of IgG directed at T. gondii, CMV, HSV-1 and -2 
84,93,194,195
. Having a mother 
who was born outside Sweden was also considered a confounding factor. Being born outside 
Sweden could imply a different exposure environment and thereby IgG levels that differ from 
those of Swedish mothers 
194,196
. The effects of gestational age and mode of delivery were 
also evaluated. The IgG levels in a newborn baby increase with gestational age 
197
. During 
vaginal delivery a boost of IgG is transferred from the mother to baby, which does not occur 
during a caesarean section 
198
. However, caeserean section was associated with neither the 
exposure, nor the outcome, and gestational age did not differ between cases and controls. 
Though we were already underpowered, these variables were not included in the analyses. 
Unfortunately, we did not have information on parental psychiatric disorders. 
It was not possible to adjust for factors that may confound the association between maternal 
exposure to infection and neonatal levels of acute phase proteins, such as medication or 
disease, in study II. 
Study III To decrease the bias due to confounding, while not losing precision of the 
estimates by including numerous confounders, we decided that the confounding factor had to 
have an association with the exposure and outcome of at least OR/HR 1.2 as well as a 
prevalence of at least 5% in the study population (Table 7). Finally,  the confounders included 
in the adjusted model were male sex 
199, born in municipality with ≥200 000 inhabitants 200, 
mother or father with psychiatric disorder (ICD-10 F00-99) 
201
, mother or father born outside 
Sweden 
196
, and hospital admission during childhood (except with infection or with 
psychiatric disorder). 
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Table 7. Prevalences of potential confounders and their association with non- affective psychoses, 
and childhood infection, HR and OR, 95% CI. (Study III) 
 
Study IV In the basic model all risk ratios were adjusted for sex of child, birth year 
standardized into centered birth year (departure from mean year=0 (referent)), and c-birth 
year squared to adjust for period and cohort effects. In this study the strategy was to include 
as many potential confounding variables as possible as we had enough power: child born 
December-May 
11
, in municipality with ≥200,000 inhabitants in 1980 200, small for 
gestational age (SGA) 
202
, either parent  ≥ 35 years at time of birth 195, either parent born 
outside Sweden 
196
, low socioeconomic status (SES) in terms of single-parent household, 
disposable family income on an individual level, and highest educational level of parents 
203
. 
In addition either parent with a diagnosis of psychiatric disorder (ICD-10 F00-99) 
201
, and 
familial tendency to seek hospital care, or to be hospitalized were considered in terms of 
hospitalization of either parent with any diagnosis other than infection or of psychiatric origin 
up to 5 years before, or during pregnancy. Associations between the various covariates and 
exposures (maternal infection up to 5 years prior to pregnancy, maternal infection during 
pregnancy, and infection during childhood), and the outcome of non-affective psychosis can 
be found in Table S5. 
6.2.3.4 Right censoring 
Right censoring takes place when, at the end of follow-up, the event (outcome), for example a 
diagnosis of non-affective psychosis, has not yet occured. In all the studies in the thesis the 
study participants were between 28 and 33 years old at end of follow-up. Consequently, the 
event might have eventually occurred had the follow-up time been longer.  
 
¹Hospital admission with all diagnoses except a diagnosis of infection or a psychiatric diagnosis 
 Non-affective 
psychosis 
HR (95% CI) 
Childhood 
infection  
OR (95% CI) 
Prevalence  
(%) 
Male sex 1.4 (1.3-1.4) 1.3 (1.3-1.3) 51 
Born Dec-May 1.1 (1.0-1.1) 1.0 (0.9-1.0) 52 
Urban birth 1.4 (1.3-1.5) 1.2 (1.2-1.3) 14 
Parental migration 2.0 (1.8-2.1) 1.2 (1.2-1.2) 9 
Parental age ≥35 Maternal 1.4 (1.3-1.5) 1.0 (1.0-1.0) 8 
Paternal 1.4 (1.3-1.5) 1.0 (1.0-1.0) 18 
Parental psychiatric 
disorder 
Maternal 3.1 (2.9-3.4) 1.5 (1.5-1-5) 8 
Paternal 2.6 (2.4-2.8) 1.3 (1.2-1.3) 9 
Socio economic status  
(SES) 
Parent 
unemployed 
2.4 (2.2-2.7) 1.3 (1.3-1.4) 3 
Household 
receiving social 
welfare benefits 
1.5 (1.4-1.6) 1.1 (1.1-1.1) 35 
Inpatient care with other diagnoses¹ 1.3 (1.2-1.4) 2.1 (2.1-2.1) 34 
Maternal infection during pregnancy 1.6 (1.2-2.0) 1.8 (1.7-1.9) 0.9 
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6.2.4 Generalizability 
Generalizability, also termed external validity, is the extent to which the results can be 
applied in a different setting such as a population from another country. Studies using a total 
population usually have good generalizability. However, in all studies the cases were 
diagnosed with non-affective psychosis before the age of 28-33 years of age. Consequently, 
the results probably cannot be generalized to non-affective psychosis developed at an older 
age.  
In addition, the study populations were born between 1975 and 1997 whereby their mothers 
were exposed to the specific strains of infections existing in Sweden at that time. Our results 
can be applicable to other Nordic countries but must be cautiously interpreted in relation to 
other regions and time periods.  
Moreover, in terms of clinical diagnosis of infection we only had data on in-patient care and 
consequently only severe infections. Thus, our results cannot be generalized to less severe 
infections. 
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7 CONCLUSION AND FUTURE DIRECTIONS 
Although infection early in life is an acknowledged risk factor for schizophrenia, no 
consistent support can be found in the literature. It is a challenging task to explore early risk 
factors for psychotic disorder, as it generally takes two to three decades for the disease to 
develop and psychotic disorder is a relatively rare condition. In addition, many factors, 
including genes and life-style related to both infection and psychosis must be included in the 
analysis in order to isolate the role of infection. In this thesis, a combination of Swedish total 
population register linkages, which allow examination of total population samples with 
prospectively gathered data on a multitude of individual parameters and with relatively long 
follow up, and biological samples from the neonatal period from a subset of individuals, 
allowing investigation of more specific research questions were used.  
We found no support for an association between maternal admission for infection during 
pregnancy and non-affective psychosis in the offspring, while hospital admission due to 
infection during childhood was modestly associated with subsequent non-affective psychosis. 
Similar results have been observed in a Danish setting 
103,166
. Associations with various 
infections and immunological alterations have guided the hypothesis towards host factors 
common to all infections rather than the particular infection per se in the causal pathway. 
Assuming that the theories of a host response to infection, such as maternal immune 
activation or a deficient immune response in the child, are correct, why do we and others find 
such modest associations with any kind of severe infection? Considering the fact that we 
investigated infections requiring hospital treatment, which are presumably more severe and 
should serve as a solid marker of individual immunologic host factors, one could expect the 
associations to be stronger.  
However, maternal infection during pregnancy, but not prior to pregnancy was associated 
with increased risk among the offspring of a susceptible group of mothers with psychiatric 
disorder. The association remained significant after adjusting for multiple socio-
environmental factors, indicating that the direct intra-uterine effect of exposure to infection in 
combination with genetic susceptibility is of relevance.  
Maternal infection with the parasite T. gondii during pregnancy doubled the relative risk of 
offspring schizophrenia. Two previous studies have reported similar results, whereby these 
findings can be considered relatively robust 
61,63
. A novel finding was the association between 
maternal exposure to CMV and schizophrenia. More recently, GWAS have observed 
interactions between gene variants and maternal CMV infection in psychosis development 
147,149
. We found no evidence of associations between HSV-1 and -2. Thus, specific infections 
or related factors may be more hazardous than others in terms of the risk of psychotic 
disorder. Another novel finding was that exposure to maternal T. gondii seemed to be harmful 
only in neonates who did not develop elevated APP levels. Similar observations were made 
of maternal CMV infection. These findings suggest that the neonatal immune response is 
crucial in relation to the risks associated with infections during foetal life. Our result requires 
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replication, in larger studies with a longer duration of follow-up and preferably from other 
populations. In addition, ascertainment of transmission of the pathogen would be valuable. 
Regarding childhood infections, bacterial and CNS infections during the pre-adolescence 
period indicated the strongest associations with non-affective psychosis. A novel finding was 
that the risk associated with childhood infections was stronger in conjunction with infection 
during foetal life, indicative of a “second-hit” model. In the future, longitudinal studies 
exploring a ”multiple-hit” model, i.e., the risks associated with successive exposures to 
infection during foetal life, childhood and adolescence, and their interaction with genetic 
variations, should have large explanatory power. Furthermore, it would be valuable to 
investigate a wider spectrum of infections ranging from the common cold to more serious 
infections that require hospitalization as well as antimicrobial treatment on the risk of 
psychosis development.  
In conclusion, the results of this thesis do not support any strong associations between 
infection early in life and non-affective psychosis overall. However, infection during foetal 
life seems to be a relevant risk factor in conjunction with genetic vulnerability and immune 
processes as well as with later exposure to infection. Notably, we had limitations in our 
studies whereby our findings must be interpreted with caution.  
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466.99, 483.99-486.09, 503.00-503.09, 540.00-540.02, 540.04-540.99, 572,99, 686.00-
686.98, 761,40, 763.10, 763.98, 778,60 
ICD-9 006-E, 006G-007X, 008W, 009-D, 084-086X, 099E-X, 110-118, 120-129, 130, 131-131X, 
132-134X, 135-136X, 370E-F, X, 372A-D, 380B, C, 381A, 382X, 420-X, 421, X, 422, 462, 
463, 466-B, 473-X, 483, 485, 486, 490, 491B, 540A, X, 572A, 647C, E, W, X, 680A, 711G-
X, 727A, 770A, 771C, E-W 
ICD-10 A06-06.5, A06.7-07.9, A08.5, A09, A59-59.9, A63, A63.8-64, B35-37.4, B37.6-38.3, 
B38.7-43.0, B43.2-45.0, B45.2-46.0, B46.2-49, B50, B50.8-57.3, B57.5, B58-58.1, B58.3-
60.1, B60.8-64, B65-69, B69.1-83.1, B83.3-83.9, B85-89, B99, H10.0, H10.3-10.9, H16.2-
16.3, H16.9, H32, H60, H60.3, H65.0, H65.1, H66.9, I30.0-30.9, I33.0-33.9, I40.0, J02*, 
J02.8-02.9*, J03*, J03.8-03.9*, J16, J16.8, J18-18.9, J20, J20.8-21, J21.8-21.9, J22, J32-
32.9*, J35.0, J37-37.1*, J40-42, K35, K35.9, K75.0, L30.3, M46.5, M65.1, M71.1, O98.3, 
O98.6-98.9, P23.8-23.9, P37.1-39.9, Z22.4, Z22.8-22.9 
 
¹ The Swedish ICD coding systems were used the following years: ICD-8 1969-86, ICD-9 1987-96 and ICD-10 1997-. 
² CNS=Central Nervous System.          
* The additional codes, B95-97.8, determines the infecting organism. 
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Table S1. All diagnoses of infection in ICD-8, -9, and -10¹. 
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x,
 u
rb
an
 b
ir
th
, p
ar
en
ta
l m
ig
ra
ti
o
n
, p
ar
en
ta
l p
sy
ch
ia
tr
ic
 h
is
to
ry
, a
n
d
 h
o
sp
it
al
 a
d
m
is
si
o
n
 w
it
h
 o
th
er
 d
ia
gn
o
se
s.
 
² 
A
d
ju
st
ed
 fo
r 
m
al
e 
se
x,
 u
rb
an
 b
ir
th
, p
ar
en
ta
l m
ig
ra
ti
o
n
, p
ar
en
ta
l p
sy
ch
ia
tr
ic
 h
is
to
ry
, h
o
sp
it
al
 a
d
m
is
si
o
n
 w
it
h
 o
th
er
 d
ia
gn
o
se
s,
 a
n
d
 in
fe
ct
io
n
 d
u
ri
n
g 
p
re
vi
o
u
s 
ti
m
e 
p
er
io
d
s.
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¹ 
A
d
ju
st
ed
 f
o
r 
y
ea
r 
o
f 
b
ir
th
 a
n
d
 s
ex
. 
 
² 
A
d
d
it
io
n
al
ly
 a
d
ju
st
ed
 f
o
r 
m
o
th
er
 o
r 
fa
th
er
 w
it
h
 p
sy
ch
o
ti
c 
d
is
o
rd
er
 (
IC
D
-1
0
 F
2
0
-2
9
).
 
³ 
A
d
d
it
io
n
al
ly
 a
d
ju
st
ed
 f
o
r 
m
o
th
er
 o
r 
fa
th
er
 w
it
h
 p
sy
ch
ia
tr
ic
 d
is
o
rd
er
 (
IC
D
-1
0
 F
0
0
-9
9
).
 
⁴
A
d
d
it
io
n
al
ly
 a
d
ju
st
ed
 f
o
r 
lo
w
 S
E
S
, 
an
d
 a
n
y
 p
ar
en
ta
l 
in
p
at
ie
n
t 
ca
re
 b
ef
o
re
 o
r 
d
u
ri
n
g
 p
re
g
n
an
cy
 e
x
ce
p
t 
fo
r 
tr
ea
tm
en
t 
o
f 
in
fe
ct
io
n
 o
r 
p
sy
ch
ia
tr
ic
 c
ar
e.
 
⁵
A
d
d
it
io
n
al
ly
 a
d
ju
st
ed
 f
o
r 
u
rb
an
 b
ir
th
, w
in
te
r 
b
ir
th
, 
p
ar
en
ta
l 
ag
e 
≥
 3
5
 y
ea
rs
, 
sm
al
l 
fo
r 
g
es
ta
ti
o
n
al
 a
g
e,
 a
n
d
 p
ar
en
t 
b
o
rn
 o
u
ts
id
e 
S
w
ed
en
 
 
 
 
 
 
 
 
 
 
 
 
T
a
b
le
 S
4
. 
A
ss
o
ci
a
ti
o
n
s 
b
et
w
ee
n
 n
o
n
-a
ff
ec
ti
v
e 
p
sy
ch
o
se
s 
a
n
d
 p
a
re
n
ta
l 
h
o
sp
it
a
l 
a
d
m
is
si
o
n
 w
it
h
 i
n
fe
ct
io
n
 
a
m
o
n
g
 i
n
d
iv
id
u
a
ls
 b
o
rn
 i
n
 S
w
ed
en
 1
9
7
8
-9
7
, 
H
a
za
rd
 R
a
ti
o
s 
(H
R
) 
a
n
d
 9
5
%
 C
I.
 (
S
tu
d
y
 I
V
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